prod.bioonc.gene1000truecrossdomain.xml2010-10-14T17:43:41.000Z"2375eb72f16c40d1367fb26d42aeec3d"101278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/blank.gif2011-10-11T03:36:15.000Z"325472601571f31e1bf00674c368d335"43278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_close.png2011-10-11T03:36:15.000Z"6e2879a324a76e9972ebc98201aae1d8"1517278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_loading.png2011-10-11T03:36:16.000Z"b1d54c240cf06e7f41e372d56919b738"10195278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_nav_left.png2011-10-11T03:36:16.000Z"3f3e406102152cd8236383568a40ba35"1446278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_nav_right.png2011-10-11T03:36:17.000Z"216e4bde5bddeeaa60dc3d692890a68e"1454278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_shadow_e.png2011-10-11T03:36:17.000Z"fd4f491080d29fade5080877f1ba4c8b"107278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_shadow_n.png2011-10-11T03:36:18.000Z"18cde16379b2ceadef714d9b346d09ec"106278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_shadow_ne.png2011-10-11T03:36:18.000Z"63adf788acf193d4e4f3642d7d793125"347278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_shadow_nw.png2011-10-11T03:36:19.000Z"c820c878aedb7a7f9ebd7135a58e7c65"324278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_shadow_s.png2011-10-11T03:36:19.000Z"9b9e5c888028aaef40fe5b6a363f1e29"111278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_shadow_se.png2011-10-11T03:36:20.000Z"a8afd5a008884380ee712d177105268f"352278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_shadow_sw.png2011-10-11T03:36:20.000Z"f81cc0fee5581d76ad3cebe47e7e791b"340278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_shadow_w.png2011-10-11T03:36:22.000Z"59b0e63eb059e58d932cfd53da4d87e6"103278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_title_left.png2011-10-11T03:36:22.000Z"1582ac2d3bef6a6445bf02ceca2741cd"503278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_title_main.png2011-10-11T03:36:23.000Z"38dad6c1ed4bdc81c0bec721b2deb8c2"96278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_title_over.png2011-10-11T03:36:23.000Z"b886fd165d4b7ac77d41fb52d87ffc60"70278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancy_title_right.png2011-10-11T03:36:24.000Z"6cbe0c935511e7f9a2555ccb6a7324c4"506278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancybox-x.png2011-10-11T03:36:24.000Z"168696d8a694214090ef90e029cdf393"203278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancybox-y.png2011-10-11T03:36:25.000Z"36a58859beb9a6b19322a37466b9f78e"176278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox/fancybox.png2011-10-11T03:36:25.000Z"11e57e492ee0311540967cc7a1e6e3e2"15287278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages/fancybox_$folder$2011-10-11T03:35:27.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDimages_$folder$2011-10-11T03:35:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/AACR2007ResearchGrant.pdf2010-03-16T20:51:04.000Z"bb453042bee741c3dffbf69817824e50"434197278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ABT-263_CLL_PhaseIandIIa.pdf2010-03-16T20:51:10.000Z"bf4e38742e4f032c1011951a7f588f59"113097278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ABT-263_LymphoidMalignancies_PhaseIandIIa.pdf2010-03-16T20:51:11.000Z"6d4c5ae1e3af7a92bce40842978765cf"106391278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ABT-263_SCLCandNonHeme_PhaseIandIIa.pdf2010-03-16T20:51:12.000Z"fa3979fc907bca19db3b7ea84e5f05f8"107871278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ABT-869_BC_PhaseII.pdf2010-03-16T20:51:13.000Z"b2694519bbfd590a687bd5f53292421d"82667278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ABT_263_Phase_IIIa_US_and_Australia.pdf2010-03-16T20:51:07.000Z"cabe2174bc4a608439849c15dc77366c"50733278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ABT_263_Phase_IIIa_US_only.pdf2010-03-16T20:51:08.000Z"0146aefc4d7b578545c4be0daa483bc9"50703278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ABT_263_Phase_I_II_US_and_UK.pdf2010-03-16T20:51:06.000Z"c5fc071fd063f4ce17ceba7abcea8a70"50717278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ABT_869_Phase_II_International.pdf2010-03-16T20:51:09.000Z"95268cb5507a3c1c104c371209ce6ad6"74681278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ACRA_Hematological-Malignancies.pdf2010-03-16T20:51:14.000Z"4d5898a8fde7aa494138a3589ccdc25c"1150035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ASCO 2008 Selected Abstracts 04-25-08.xls2010-03-16T20:51:21.000Z"1966575062b9b482eb00cd4f1b5c1fa1"60416278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ASH/ASH_Abstracts_120208.xls2010-03-16T20:51:32.000Z"bb00897181b394cecf8f679471c6e21b"153088278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ASH/ASH_Abstracts_120508.xls2010-03-16T20:51:33.000Z"b600e9d9ad4cb7e98f39fbb7f3b85017"147456278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ASH_$folder$2010-03-16T20:51:22.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Apo2LTRAIL_NHL_PhaseIbandII.pdf2010-03-16T20:51:17.000Z"4983d331f6709f452b303de485e8833f"117454278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Apomab_NHL_PhaseII.pdf2010-03-16T20:51:19.000Z"e0a6351d84e901c0c383d821f8f41144"103033278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Apomab_Phase_ II_ US_and_ Australia.pdf2010-03-16T20:51:20.000Z"45d5d4e1f7743be3f996aee7fbb464bc"46794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/BIONC-21473_M05$w_DR_022504.pdf2010-03-16T20:52:16.000Z"d1775eababa6d0eef88ced7e1302b853"76791278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/BIONC22395_ASCO$ease_050604.pdf2010-03-16T20:52:17.000Z"452fa6ec5d4ede2f728c885420a604c7"67002278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Bevacizumab_ OvCa _PhaseIII.pdf2010-03-16T20:52:08.000Z"c53acb7567c265cec1ef4b1f0d619b39"115807278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Bevacizumab_BC_PhaseIII.pdf2010-03-16T20:52:09.000Z"71994c3c2a1bc1c9e4adf50f97fed9ac"108504278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Bevacizumab_CRC_PhaseIII.pdf2010-03-16T20:52:11.000Z"d3c71c6ec00b0cd18aa19ded8c23e89c"122897278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Bevacizumab_Gastric_PhaseIII.pdf2010-03-16T20:52:12.000Z"05c232f16b2241635af358f40037a427"114650278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Bevacizumab_MM_PhaseII.pdf2010-03-16T20:52:13.000Z"eb7d5af91616072826896375c1f5e2e4"98263278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Bevacizumab_NHL_PhaseIII.pdf2010-03-16T20:52:14.000Z"e3ef987c21d4fbddacc375d2f9a9954f"110462278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Bevacizumab_NSCLCandCRC_PhaseIV.pdf2010-03-16T20:52:15.000Z"b6e683f1254d466986a0aaaccb72d371"128159278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/BioOncClinicalTrials.pdf2010-03-16T20:52:18.000Z"4c404ea64308e83bc45d1cf90961871b"4365542278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Colorectal_Fact_Sheet.pdf2010-03-16T20:52:39.000Z"4334e6271e66ce373dddf1db111c6444"64260278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Erlotinib_2ndLine _NSCLC_PhaseIII.pdf2010-03-16T20:52:40.000Z"787c6e4ac294624049949406f8a5f057"121985278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Erlotinib_Adjuvant _NSCLC_PhaseIII.pdf2010-03-16T20:52:42.000Z"c2b849f0cd9fc2e6d5fd799a155f0ade"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/GDC-0449_MCRC_PhaseII.pdf2010-03-16T20:52:59.000Z"08ecc440f11351c803eaea21924409a5"121380278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/GDC-0449_OvCa_PhaseII.pdf2010-03-16T20:53:00.000Z"d5f45e8e92f095f7b5483291e40b0950"109687278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Genentech_Poster.pdf2010-03-16T20:53:02.000Z"11660522743946832ffe784c6eff94f4"226887278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/GrantApp_7_06.pdf2010-03-16T20:53:05.000Z"f2841dad3522f8e644c86b7600ae8886"526268278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Grant_AppForm2.pdf2010-03-16T20:53:03.000Z"aa9fce650a697877cf25bfbd6eb04b47"38575278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Guide_for_Interpreting_Common_Statistics_Measures_in_Clinical_Trials.pdf2010-03-16T20:53:07.000Z"b57a155f4ea1a94c5ded5538b3d749af"256334278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Hedgehog_antagonist_Phase_II_US_and_Brazil.pdf2010-03-16T20:53:09.000Z"98557d805a3aeebd43edd59f464c89ea"53875278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Hedgehog_antagonist_Phase_II_US_only.pdf2010-03-16T20:53:09.000Z"4e1e5d69a6d80e1a29577c48853a12f6"53808278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/PERTUZUMAB_Phase_III_International.pdf2010-03-16T20:53:23.000Z"aacf0161ee1a5bf19e99a3f05436a34b"82063278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/PRO131921 _Phase _III _US _only_NHL.pdf2010-03-16T20:53:24.000Z"043ecb332b03c6cd0273a04a544862d2"46688278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/PRO131921_CLL_PhaseIandII.pdf2010-03-16T20:53:25.000Z"1b9605b53efff03df8cff061277bf493"93448278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/PRO131921_NHL_PhaseIandII.pdf2010-03-16T20:53:27.000Z"1abb6719912181099018a57f808c1c2b"104609278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/PRO131921_Phase_III_US_only_CLL.pdf2010-03-16T20:53:28.000Z"7c43f92fc0b60ebe4c238878410a6062"45656278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/ResearchGrants.pdf2010-03-16T20:53:29.000Z"3f2e15d3c784cfbab58d046d7d9db491"124285278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN-40_DLBCL_PhaseIIb.pdf2010-03-16T21:03:39.000Z"8d3d17c457b4047c6359fd8e4bbce669"127122278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN-40_DLBCL_PhaseIb.pdf2010-03-16T21:03:37.000Z"2429a44660d2167c7f5749bfacff684d"100672278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN-40_MM_PhaseI.pdf2010-03-16T21:03:40.000Z"8d79ab6e9961cef45ba64c765bb07fcc"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN-40_MM_PhaseIb.pdf2010-03-16T21:03:41.000Z"0d11509f68ada61fec0069466bfea871"107612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN-40_NHL_PhaseIb.pdf2010-03-16T21:03:43.000Z"e5239c86c79906f5b30db138b62da94c"107683278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN_40_Phase_IIb_International.pdf2010-03-16T21:03:36.000Z"f4625b13c50156bb7cabb907ca2af44d"54406278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN_40_Phase_I_US_only.pdf2010-03-16T21:03:31.000Z"5821a9684051417e14915a1182c3ec5f"50387278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN_40_Phase_Ib_US_and_the_Netherlands.pdf2010-03-16T21:03:32.000Z"ec5a07a35c552dcbeef88e01d082d053"54556278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN_40_Phase_Ib_US_only_DLBCL.pdf2010-03-16T21:03:33.000Z"0366b30266534906118c90061ebe165d"52055278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/SGN_40_Phase_Ib_US_only_NHL.pdf2010-03-16T21:03:34.000Z"bfc763cbeebd124853ad7c9d413e43bc"52294278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/T-DM1_HER2+withoutpriorchemo_MBC_PhaseII.pdf2010-03-16T21:03:49.000Z"dec189454d45fdb85cd59d71da7bc6e0"111547278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/TDM-1_HER2+_MBC_PhaseII.pdf2010-03-16T21:04:06.000Z"53db40d2ac370c0658e5328f3dc3eac6"116666278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/T_DM1_Phase_II_International.pdf2010-03-16T21:03:47.000Z"6167a19d904bee16c2441e8c4bf6ea75"72554278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/T_DM1_Phase_II_US_only.pdf2010-03-16T21:03:48.000Z"f34b4a05bb808980909635a28c87c2d1"70338278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/TarcEdMat_NSCLCBrochure.pdf2010-03-16T21:03:50.000Z"fd542317d9fa1c0eaacfd5e13ed9cf9a"2981023278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/TarcEdMat_PatBrochure.pdf2010-03-16T21:03:56.000Z"8e503f3ff1d284b98bb50de3bcfed7d4"1333974278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/TarcEdMat_PatTearPad.pdf2010-03-16T21:03:59.000Z"583df506e001f03796845eab3d8c42d7"212213278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/TarcEdMat_SpocBrochure.pdf2010-03-16T21:04:00.000Z"4642065f2d99597b1f6a30a9c447bde7"1657878278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Tarceva_PI.pdf2010-03-16T21:04:04.000Z"a55b08f0fb7a47b5dd3b71caa0f50326"272502278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Trastuzumab_1stLine _MBC_PhaseIII.pdf2010-03-16T21:04:23.000Z"28752f95257c44d239395ec790719a8c"101962278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Trastuzumab_Adjuvant _BC_PhaseIII.pdf2010-03-16T21:04:25.000Z"f81e2ebc6eeba5b831add4e0d2aa66f3"120901278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/Trastuzumab_RecurrentorMetastatic _BC_PhaseIII.pdf2010-03-16T21:04:26.000Z"58805cabd72878b6b103392847230f09"105310278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/avaphysicianSlideKit.pdf2010-03-16T20:51:35.000Z"d8479650c46b6b82ab0b09f6f29c029b"1970612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/biooncology-banner.swf2010-03-16T20:51:51.000Z"e4ae2aea4a6381a14f0b63d7f3fb4dc5"33568278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/all-wcprops2010-03-16T20:51:55.000Z"5186ffaa2183044d73e28b2b3868b9c5"348278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/entries2010-03-16T20:51:59.000Z"763084cc64f1f9d5fd281a8906505097"423278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/prop-base_$folder$2010-03-16T20:52:00.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/props_$folder$2010-03-16T20:52:01.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/text-base/banner.xml.svn-base2010-03-16T20:52:03.000Z"6f1256045ea982ee6730aa51de5617f8"4464278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/text-base_$folder$2010-03-16T20:52:02.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/tmp/prop-base_$folder$2010-03-16T20:52:05.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/tmp/props_$folder$2010-03-16T20:52:05.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/tmp/text-base_$folder$2010-03-16T20:52:06.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn/tmp_$folder$2010-03-16T20:52:04.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/.svn_$folder$2010-03-16T20:51:53.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml/banner.xml2010-03-16T20:52:06.000Z"6f1256045ea982ee6730aa51de5617f8"4464278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner/xml_$folder$2010-03-16T20:51:52.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/banner_$folder$2010-03-16T20:51:41.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/biooncology-splash-1.swf2010-03-16T20:52:26.000Z"2caa8afa8559898df0ed5c889fa7083e"289519278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/biooncology-splash-2.swf2010-03-16T20:52:28.000Z"62b3b07135a26612ed50067173e3ecd0"415235278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/chart_3.pdf2010-03-16T20:52:31.000Z"19f06076f462f90ba38ae9b15e57d6d4"2322973278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/facingMCRC.pdf2010-03-16T20:52:43.000Z"76c0af87e5e06d9eb7381e0dabdee205"161128278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/flowplayer/flowplayer.controls.swf2010-03-16T20:52:57.000Z"0e88f2ed2b1ec37d3259a1d20ae0f5c7"26583278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/flowplayer/flowplayer.swf2010-03-16T20:52:58.000Z"f09e9408e59396dc3be7619a40b95b45"110762278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/flowplayer_$folder$2010-03-16T20:52:44.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/herceptin-slide-kit.pdf2010-03-16T20:53:10.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resource-library.swf2010-03-16T20:53:31.000Z"95b08f55818159dd23ef1d6875ad21de"24843278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/avastin/avastin-dosing.pdf2010-03-16T20:54:05.000Z"66089f8c744f9d927601afda40c77e3f"636830278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/avastin/avastin-moa-brochure.pdf2010-03-16T20:54:11.000Z"26d031dd895dad1b9aa1bd0f3750e188"1109077278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/avastin/avastin-pi.pdf2010-03-16T20:54:18.000Z"f0a86a766eea99c6db6ad3b56f0db566"306721278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/avastin/avastin-promo-pi.pdf2010-03-16T20:54:20.000Z"e00742790d858dd116cf656d8e3bb3e6"148513278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/avastin_$folder$2010-03-16T20:53:39.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/biooncology/biooncology-poster.pdf2010-03-16T20:54:42.000Z"62774dc3a1449a27be061d14307d8ac7"614488278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/biooncology/biooncology-staging-guidelines.pdf2010-03-16T20:54:47.000Z"f5eae4859ae802f9d12e72e4bbf289b5"973562278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/biooncology/biooncology-targeted-agents.pdf2010-03-16T20:54:53.000Z"1611603248eaab4cc185c75692b93874"1201993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/biooncology_$folder$2010-03-16T20:54:21.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/BCIRG_Sales_Aid_2009.pdf2010-03-16T20:55:36.000Z"2c59410871699cca7993a347dcd4e241"269942278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-adjuvant-english.pdf2010-03-16T20:55:37.000Z"8b2f5a12cdbc5b2412838362f6df8830"1528882278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-adjuvant-spanish.pdf2010-03-16T20:55:41.000Z"e14a72178efb66ccd7017e9acfd502f4"1831910278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-administration.pdf2010-03-16T20:55:45.000Z"6dd7725768b7ce46883a33646ec88aa6"377548278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-bcirg.pdf2010-03-16T20:55:46.000Z"3ccfe628504a07298cc730d0e1f988f5"75345278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-metastatic-english.pdf2010-03-16T20:55:48.000Z"9da7dfb071094ef22a0f57d05ef331fe"479992278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-metastatic-spanish.pdf2010-03-16T20:55:50.000Z"e4d595b501816084d7885e3922d0a4cc"944471278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-metastatic.pdf2010-03-16T20:55:53.000Z"09b0e10ffe011263d6deb3095826bc37"291924278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-pi.pdf2010-03-16T20:55:54.000Z"63d99938bac56e30a600cef260ff3a30"375813278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-promo-pi.pdf2010-03-16T20:55:57.000Z"52984ef23f8f06bb14b15fdb20ffa4e4"233449278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin/herceptin-slide-kit.pdf2010-03-16T20:55:59.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/herceptin_$folder$2010-03-16T20:54:57.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/menu-card/menu-card-avastin.pdf2010-04-07T22:56:38.000Z"820191f146c2cf63dde40e4a5986dcc0"724535278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/menu-card/menu-card-herceptin.pdf2010-04-07T22:56:40.000Z"8fd8258618191ee350b13b22d9279c33"753057278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/menu-card/menu-card-rituxan.pdf2010-03-16T20:57:08.000Z"3d515f8718641d22fe4f53fb8a80102b"700467278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/menu-card/menu-card-tarceva.pdf2010-04-07T22:56:43.000Z"1c051b1c88487cdb5b6b317d176306e5"721884278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/menu-card_$folder$2010-03-16T20:56:30.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/rituxan/rituxan-antibody.pdf2010-03-16T20:59:03.000Z"8709477dd1e515108b4b82e989316537"5392799278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/rituxan/rituxan-diagnostic.pdf2010-03-16T20:59:26.000Z"b106e52280fba0e8aad14bb33f398ad4"406858278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/rituxan/rituxan-dosing.pdf2010-03-16T20:59:28.000Z"b542dd87959d42a1727a975da233c829"383849278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/rituxan/rituxan-nhl-english.pdf2010-03-16T20:59:31.000Z"09f424bd8c51737d810ceda40c95da28"5075663278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/rituxan/rituxan-nhl-spanish.pdf2010-03-16T20:59:46.000Z"e4243938628b9f47838feaa32d6dbd91"8308345278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/rituxan/rituxan-pi.pdf2010-03-16T21:00:14.000Z"60de9fc0f35c5e46cb6d74947bf4266b"209250278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/rituxan/rituxan-promo-pi.pdf2010-03-16T21:00:16.000Z"9659b0ccb1de1254c9da3aea5a61cfd8"294218278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/rituxan_$folder$2010-03-16T20:57:16.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/tarceva/tarceva-champion-kit.pdf2010-03-16T21:01:02.000Z"d7212bc5de6d5832c2c52f2db3680e6d"1641993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/tarceva/tarceva-dosing.pdf2010-03-16T21:01:09.000Z"5acb48bd71a27a98bdc4d05c1f72f5d8"342787278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/tarceva/tarceva-nsclc-moa.pdf2010-03-16T21:01:11.000Z"e6352941a6163d46716aec3d7b768573"676096278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/tarceva/tarceva-nsclc.pdf2010-03-16T21:01:15.000Z"acf888034d84e1b8536a4ebe04055dad"421468278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/tarceva/tarceva-pc.pdf2010-03-16T21:01:19.000Z"f7753d8f13adecf268e0ee2388f0bb98"294040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/tarceva/tarceva-pi.pdf2010-03-16T21:01:22.000Z"d55b25610d0d6c57748eb5622b8443f1"2895045278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/tarceva/tarceva-promo-pi.pdf2010-03-16T21:01:40.000Z"a045dcdf5e975c4eda78dbf08019c0a3"3400035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/tarceva/tarceva-rash.pdf2010-03-16T21:02:08.000Z"c11aee7f57dd2ea52214ce92e1481514"1479745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/tarceva_$folder$2010-03-16T21:00:18.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/xeloda/xeloda-brochure.pdf2010-03-16T21:02:31.000Z"bf5e4dd5cc9f34a7dd0e15929a7cfb70"3766040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/xeloda/xeloda-dosing.pdf2010-03-16T21:02:39.000Z"ce3787c0b335eef167ee561d69f72cbb"212908278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/xeloda/xeloda-is.pdf2010-03-16T21:02:41.000Z"77f67637b3512116d005acb887631a1b"586976278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/xeloda/xeloda-moa.pdf2010-03-16T21:02:43.000Z"9601ba6c29ff03591464a445085940cf"71030278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/xeloda/xeloda-promo-pi.pdf2010-03-16T21:02:44.000Z"3966b2d3f6be8276925b466d329a8c70"5862223278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/xeloda/xeloda-support.pdf2010-03-16T21:03:07.000Z"94a8684dd01699bdc99308003037bb73"4452414278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/xeloda/xeloda-tp.pdf2010-03-16T21:03:21.000Z"76e6045c1e5358cbdb75eec5ffb3fa95"1149226278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources/xeloda_$folder$2010-03-16T21:02:14.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/resources_$folder$2010-03-16T20:53:32.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/startingTherapyWithAvastin.pdf2010-03-16T21:03:44.000Z"feb1e5f35e7b24a057c9fbe35d0a871e"600844278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/timeline/timeline.swf2010-03-16T21:04:15.000Z"d5d70aeef08bff987f8c5e8e78247b2d"114441278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/timeline/xml/timeline.xml2010-03-16T21:04:23.000Z"f1cb30b52f3f6b15b178b2284f1a0f2c"11794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/timeline/xml_$folder$2010-03-16T21:04:16.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/timeline_$folder$2010-03-16T21:04:07.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis-moa/angiogenesis_moa_animation.flv2010-03-16T23:43:53.000Z"1debdd1e7293bf3f16c0fcfc85e493c8"6855809278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis-moa/angiogenesis_moa_animation.mov2010-03-16T23:44:04.000Z"cb9b8f602e4aa016a4fbe6339db91b48"59216508278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis-moa/angiogenesis_moa_animation.wmv2010-03-16T23:45:34.000Z"c4a1664acc2ee6587fb6bb0b9b40bf21"16933637278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis-moa/config.xml2010-03-16T23:45:56.000Z"c34fe6c4278f22be01654a286f918d0d"298278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis-moa_$folder$2010-03-16T23:43:52.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis/VEGF_Angiogenesis_Seq1.flv2010-03-16T23:43:19.000Z"b43362e5fefda2f5a80a25cf7515cad9"5261076278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis/VEGF_Angiogenesis_Seq1.mp42010-03-16T23:43:26.000Z"d8b0763e318dd8d4fb87cdeaf1737b04"7066400278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis/VEGF_Angiogenesis_Seq1.wmv2010-03-16T23:43:37.000Z"33cee34aa04b106d60daa3ea86151d0e"8743815278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis/config.xml2010-03-16T23:43:18.000Z"e30c3dac050dff1d8fb9ab3c4294e9cd"285278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/angiogenesis_$folder$2010-03-16T23:43:18.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis-anim/apoptosis-anim.flv2010-03-16T23:46:22.000Z"3a15291e2aa9cdd1b3ad23c688d7e509"4881784278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis-anim/apoptosis-anim.mov2010-03-16T23:46:31.000Z"e6577f5e65da8415d1757171b9c16328"9653819278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis-anim/apoptosis-anim.wmv2010-03-16T23:46:49.000Z"fc3273a3c1bb8e96ccce9db14beaffa2"18901572278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis-anim/config.xml2010-03-16T23:47:13.000Z"b884cb5f4c4dfff0380cb66c0d849532"277278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis-anim_$folder$2010-03-16T23:46:22.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis/apoptosis_seq1.flv2010-03-16T23:45:57.000Z"29a365fcf88a451f0a78f200f21fce41"4423671278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis/apoptosis_seq1.mp42010-03-16T23:46:04.000Z"7ccec10b4a21c9144c3069161fd9d4b4"5858071278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis/apoptosis_seq1.wmv2010-03-16T23:46:13.000Z"daa2e188e298b9ec576281c4f484d77c"5929935278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis/config.xml2010-03-16T23:46:21.000Z"bebc1bac67cb125342aa3257896da1f1"271278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/apoptosis_$folder$2010-03-16T23:45:57.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/b-cell/b-cell-animation.flv2010-03-16T23:47:14.000Z"dbc5651a0cd166766c684c48978b2c5e"6437502278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/b-cell/b-cell-animation.mov2010-03-16T23:47:27.000Z"19e5a4329fed00a85428d08a5c7436da"33059594278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/b-cell/b-cell-animation.wmv2010-03-16T23:48:33.000Z"b265921b865a5b3967f25f2f96d8444a"10165613278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/b-cell/config.xml2010-03-16T23:48:55.000Z"d0002c93f05c8c12c81584e165cd3058"266278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/b-cell_$folder$2010-03-16T23:47:13.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd20/cd20.flv2010-03-16T23:48:56.000Z"f22e67400b73fae60a6573896357e586"4368071278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd20/cd20.mov2010-03-16T23:49:10.000Z"4bca77970e0f6bed5b043300ff871ffa"8837933278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd20/cd20.wmv2010-03-16T23:49:38.000Z"cf2cc9e173640102471dbad0ff736d64"14901476278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd20/config.xml2010-03-16T23:50:21.000Z"2ede6b1bc6f03bebdedb4fa75f6e0357"249278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd20_$folder$2010-03-16T23:48:55.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd40/cd40.flv2010-03-16T23:50:22.000Z"e2de67c7d8332f256a3ecb31b2d561a1"2686108278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd40/cd40.mov2010-03-16T23:50:27.000Z"881fb2442becfc82557a19b19aaf9a2d"5293068278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd40/cd40.wmv2010-03-16T23:50:33.000Z"99e50e1a6b08a6c53a09c68d15759ee3"9573350278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd40/config.xml2010-03-16T23:50:50.000Z"c64343fb88060e4b5993c348bb34c773"254278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/cd40_$folder$2010-03-16T23:50:22.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hdi/config.xml2010-03-16T23:50:52.000Z"e14f6b3678e03ed5fbe557b5cad62690"261278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hdi/hdi_07-26-2007.flv2010-03-16T23:50:52.000Z"564dfe5929922c9cfb6a3c9fe33f81f8"14203923278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hdi/hdi_07-26-2007.mp42010-03-16T23:51:16.000Z"f0aabf4df154e51af4a865d163fd02f3"30582286278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hdi/hdi_07-26-2007.wmv2010-03-16T23:51:56.000Z"debff5dc63bb0fe0fa777b66f3dfee3d"30675717278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hdi_$folder$2010-03-16T23:50:51.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hedgehog/config.xml2010-03-16T23:52:34.000Z"d5a2c7690684fb97d0ed5bf0e7c00e41"264278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hedgehog/hedgehog.flv2010-03-16T23:52:35.000Z"311a72ea9b293fde9df0f1188478e0bb"4060037278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hedgehog/hedgehog.mov2010-03-16T23:52:40.000Z"a0b5cc8b5c2ca5096e55e97def385373"4686895278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hedgehog/hedgehog.wmv2010-03-16T23:52:47.000Z"8d703f3c6143b2327adc924c5beff1e4"15605488278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/hedgehog_$folder$2010-03-16T23:52:34.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her-pathways/config.xml2010-03-16T23:53:06.000Z"16f56dfe10f1cae3738cc84227775789"270278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her-pathways/her-pathways.flv2010-03-16T23:53:07.000Z"2ce983d5f8323a66bd00e8d840fb1034"2904196278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her-pathways/her-pathways.mov2010-03-16T23:53:11.000Z"75f5ab2ab5ea82540d7f605e8a6ede91"5238487278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her-pathways/her-pathways.wmv2010-03-16T23:53:18.000Z"8518ed033e9037aa57d35c827e16e6fa"13237428278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her-pathways_$folder$2010-03-16T23:53:06.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her1/config.xml2010-03-16T23:53:34.000Z"16418c69e36d9fe1c484a5621c862317"262278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her1/her1-animation.flv2010-03-16T23:53:35.000Z"8ef74b03f4a98bf4832bf1bb3d9c60c5"6449826278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her1/her1-animation.mov2010-03-16T23:53:46.000Z"00d21088799c4644a20fadecfda5f609"19062358278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her1/her1-animation.wmv2010-03-16T23:54:17.000Z"f572fe34e212d22abba98cc9b413879f"4173451278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her1_$folder$2010-03-16T23:53:34.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her2/config.xml2010-03-16T23:54:25.000Z"938fab7833acdbc180d326c046770c01"262278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her2/her2-animation.flv2010-03-16T23:54:26.000Z"537bbffe13115ccf4c6dc426d6db9558"5819036278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her2/her2-animation.mov2010-03-16T23:54:36.000Z"7208a2c476cab0bef9d7505046acc980"49679118278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her2/her2-animation.wmv2010-03-16T23:56:02.000Z"a89981b8c3771779f7fe7f8be494c472"13805571278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/her2_$folder$2010-03-16T23:54:24.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/player_$folder$2010-03-16T23:56:33.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/tdm-1/config.xml2010-03-16T23:56:34.000Z"7b347fbae83585c3de4d82cd0951f00d"252278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/tdm-1/tdm-1.flv2010-03-16T23:56:34.000Z"9929ff56bb17367da3479f499e54afbc"2416525278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/tdm-1/tdm-1.mov2010-03-16T23:56:39.000Z"987583207d484514724e17d6d60d3c9e"3133492278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/tdm-1/tdm-1.wmv2010-03-16T23:56:45.000Z"f4c6e90e3e323ba275550127b646e2b7"9493344278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video/tdm-1_$folder$2010-03-16T23:56:33.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312/video_$folder$2010-03-16T20:53:08.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100312_$folder$2010-03-12T17:27:18.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/AACR2007ResearchGrant.pdf2010-05-05T23:39:48.000Z"bb453042bee741c3dffbf69817824e50"434197278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ABT-263_CLL_PhaseIandIIa.pdf2010-05-05T23:39:53.000Z"bf4e38742e4f032c1011951a7f588f59"113097278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ABT-263_LymphoidMalignancies_PhaseIandIIa.pdf2010-05-05T23:39:55.000Z"6d4c5ae1e3af7a92bce40842978765cf"106391278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ABT-263_SCLCandNonHeme_PhaseIandIIa.pdf2010-05-05T23:39:55.000Z"fa3979fc907bca19db3b7ea84e5f05f8"107871278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ABT-869_BC_PhaseII.pdf2010-05-05T23:39:57.000Z"b2694519bbfd590a687bd5f53292421d"82667278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ABT_263_Phase_IIIa_US_and_Australia.pdf2010-05-05T23:39:51.000Z"cabe2174bc4a608439849c15dc77366c"50733278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ABT_263_Phase_IIIa_US_only.pdf2010-05-05T23:39:52.000Z"0146aefc4d7b578545c4be0daa483bc9"50703278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ABT_263_Phase_I_II_US_and_UK.pdf2010-05-05T23:39:49.000Z"c5fc071fd063f4ce17ceba7abcea8a70"50717278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ABT_869_Phase_II_International.pdf2010-05-05T23:39:52.000Z"95268cb5507a3c1c104c371209ce6ad6"74681278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ACRA_Hematological-Malignancies.pdf2010-05-05T23:39:58.000Z"4d5898a8fde7aa494138a3589ccdc25c"1150035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ASCO 2008 Selected Abstracts 04-25-08.xls2010-05-05T23:40:04.000Z"1966575062b9b482eb00cd4f1b5c1fa1"60416278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ASH/ASH_Abstracts_120208.xls2010-05-05T23:40:05.000Z"bb00897181b394cecf8f679471c6e21b"153088278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ASH/ASH_Abstracts_120508.xls2010-05-05T23:40:08.000Z"b600e9d9ad4cb7e98f39fbb7f3b85017"147456278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ASH_$folder$2010-05-05T23:40:05.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Apo2LTRAIL_NHL_PhaseIbandII.pdf2010-05-05T23:40:01.000Z"4983d331f6709f452b303de485e8833f"117454278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Apomab_NHL_PhaseII.pdf2010-05-05T23:40:02.000Z"e0a6351d84e901c0c383d821f8f41144"103033278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Apomab_Phase_ II_ US_and_ Australia.pdf2010-05-05T23:40:03.000Z"45d5d4e1f7743be3f996aee7fbb464bc"46794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/BIONC-21473_M05$w_DR_022504.pdf2010-05-05T23:40:29.000Z"d1775eababa6d0eef88ced7e1302b853"76791278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/BIONC22395_ASCO$ease_050604.pdf2010-05-05T23:40:30.000Z"452fa6ec5d4ede2f728c885420a604c7"67002278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Bevacizumab_ OvCa _PhaseIII.pdf2010-05-05T23:40:22.000Z"c53acb7567c265cec1ef4b1f0d619b39"115807278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Bevacizumab_BC_PhaseIII.pdf2010-05-05T23:40:23.000Z"71994c3c2a1bc1c9e4adf50f97fed9ac"108504278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Bevacizumab_CRC_PhaseIII.pdf2010-05-05T23:40:25.000Z"d3c71c6ec00b0cd18aa19ded8c23e89c"122897278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Bevacizumab_Gastric_PhaseIII.pdf2010-05-05T23:40:25.000Z"05c232f16b2241635af358f40037a427"114650278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Bevacizumab_MM_PhaseII.pdf2010-05-05T23:40:26.000Z"eb7d5af91616072826896375c1f5e2e4"98263278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Bevacizumab_NHL_PhaseIII.pdf2010-05-05T23:40:27.000Z"e3ef987c21d4fbddacc375d2f9a9954f"110462278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Bevacizumab_NSCLCandCRC_PhaseIV.pdf2010-05-05T23:40:28.000Z"b6e683f1254d466986a0aaaccb72d371"128159278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/BioOncClinicalTrials.pdf2010-05-05T23:40:31.000Z"4c404ea64308e83bc45d1cf90961871b"4365542278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Colorectal_Fact_Sheet.pdf2010-05-05T23:40:55.000Z"4334e6271e66ce373dddf1db111c6444"64260278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Erlotinib_2ndLine _NSCLC_PhaseIII.pdf2010-05-05T23:40:56.000Z"787c6e4ac294624049949406f8a5f057"121985278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Erlotinib_Adjuvant _NSCLC_PhaseIII.pdf2010-05-05T23:40:58.000Z"c2b849f0cd9fc2e6d5fd799a155f0ade"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/GDC-0449_MCRC_PhaseII.pdf2010-05-05T23:41:03.000Z"08ecc440f11351c803eaea21924409a5"121380278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/GDC-0449_OvCa_PhaseII.pdf2010-05-05T23:41:04.000Z"d5f45e8e92f095f7b5483291e40b0950"109687278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Genentech_Poster.pdf2010-05-05T23:41:05.000Z"11660522743946832ffe784c6eff94f4"226887278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/GrantApp_7_06.pdf2010-05-05T23:41:07.000Z"f2841dad3522f8e644c86b7600ae8886"526268278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Grant_AppForm2.pdf2010-05-05T23:41:06.000Z"aa9fce650a697877cf25bfbd6eb04b47"38575278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Guide_for_Interpreting_Common_Statistics_Measures_in_Clinical_Trials.pdf2010-05-05T23:41:09.000Z"b57a155f4ea1a94c5ded5538b3d749af"256334278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Hedgehog_antagonist_Phase_II_US_and_Brazil.pdf2010-05-05T23:41:10.000Z"98557d805a3aeebd43edd59f464c89ea"53875278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Hedgehog_antagonist_Phase_II_US_only.pdf2010-05-05T23:41:11.000Z"4e1e5d69a6d80e1a29577c48853a12f6"53808278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/PERTUZUMAB_Phase_III_International.pdf2010-05-05T23:41:25.000Z"aacf0161ee1a5bf19e99a3f05436a34b"82063278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/PRO131921 _Phase _III _US _only_NHL.pdf2010-05-05T23:41:26.000Z"043ecb332b03c6cd0273a04a544862d2"46688278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/PRO131921_CLL_PhaseIandII.pdf2010-05-05T23:41:27.000Z"1b9605b53efff03df8cff061277bf493"93448278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/PRO131921_NHL_PhaseIandII.pdf2010-05-05T23:41:28.000Z"1abb6719912181099018a57f808c1c2b"104609278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/PRO131921_Phase_III_US_only_CLL.pdf2010-05-05T23:41:29.000Z"7c43f92fc0b60ebe4c238878410a6062"45656278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/ResearchGrants.pdf2010-05-05T23:41:29.000Z"3f2e15d3c784cfbab58d046d7d9db491"124285278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN-40_DLBCL_PhaseIIb.pdf2010-05-05T23:43:37.000Z"8d3d17c457b4047c6359fd8e4bbce669"127122278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN-40_DLBCL_PhaseIb.pdf2010-05-05T23:43:36.000Z"2429a44660d2167c7f5749bfacff684d"100672278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN-40_MM_PhaseI.pdf2010-05-05T23:43:38.000Z"8d79ab6e9961cef45ba64c765bb07fcc"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN-40_MM_PhaseIb.pdf2010-05-05T23:43:39.000Z"0d11509f68ada61fec0069466bfea871"107612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN-40_NHL_PhaseIb.pdf2010-05-05T23:43:40.000Z"e5239c86c79906f5b30db138b62da94c"107683278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN_40_Phase_IIb_International.pdf2010-05-05T23:43:35.000Z"f4625b13c50156bb7cabb907ca2af44d"54406278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN_40_Phase_I_US_only.pdf2010-05-05T23:43:31.000Z"5821a9684051417e14915a1182c3ec5f"50387278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN_40_Phase_Ib_US_and_the_Netherlands.pdf2010-05-05T23:43:32.000Z"ec5a07a35c552dcbeef88e01d082d053"54556278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN_40_Phase_Ib_US_only_DLBCL.pdf2010-05-05T23:43:33.000Z"0366b30266534906118c90061ebe165d"52055278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/SGN_40_Phase_Ib_US_only_NHL.pdf2010-05-05T23:43:34.000Z"bfc763cbeebd124853ad7c9d413e43bc"52294278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/T-DM1_HER2+withoutpriorchemo_MBC_PhaseII.pdf2010-05-05T23:43:46.000Z"dec189454d45fdb85cd59d71da7bc6e0"111547278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/TDM-1_HER2+_MBC_PhaseII.pdf2010-05-05T23:44:05.000Z"53db40d2ac370c0658e5328f3dc3eac6"116666278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/T_DM1_Phase_II_International.pdf2010-05-05T23:43:44.000Z"6167a19d904bee16c2441e8c4bf6ea75"72554278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/T_DM1_Phase_II_US_only.pdf2010-05-05T23:43:45.000Z"f34b4a05bb808980909635a28c87c2d1"70338278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/TarcEdMat_NSCLCBrochure.pdf2010-05-05T23:43:47.000Z"fd542317d9fa1c0eaacfd5e13ed9cf9a"2981023278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/TarcEdMat_PatBrochure.pdf2010-05-05T23:43:56.000Z"8e503f3ff1d284b98bb50de3bcfed7d4"1333974278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/TarcEdMat_PatTearPad.pdf2010-05-05T23:43:59.000Z"583df506e001f03796845eab3d8c42d7"212213278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/TarcEdMat_SpocBrochure.pdf2010-05-05T23:44:00.000Z"4642065f2d99597b1f6a30a9c447bde7"1657878278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Tarceva_PI.pdf2010-05-05T23:44:03.000Z"a55b08f0fb7a47b5dd3b71caa0f50326"272502278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Trastuzumab_1stLine _MBC_PhaseIII.pdf2010-05-05T23:44:08.000Z"28752f95257c44d239395ec790719a8c"101962278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Trastuzumab_Adjuvant _BC_PhaseIII.pdf2010-05-05T23:44:11.000Z"f81e2ebc6eeba5b831add4e0d2aa66f3"120901278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/Trastuzumab_RecurrentorMetastatic _BC_PhaseIII.pdf2010-05-05T23:44:13.000Z"58805cabd72878b6b103392847230f09"105310278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/avaphysicianSlideKit.pdf2010-05-05T23:40:10.000Z"d8479650c46b6b82ab0b09f6f29c029b"1970612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/banner/biooncology-banner.swf2010-05-05T23:40:20.000Z"e4ae2aea4a6381a14f0b63d7f3fb4dc5"33568278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/banner/xml/banner.xml2010-05-05T23:40:22.000Z"6f1256045ea982ee6730aa51de5617f8"4464278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/banner/xml_$folder$2010-05-05T23:40:21.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/banner_$folder$2010-05-05T23:40:20.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/biooncology-splash-1.swf2010-05-05T23:40:43.000Z"2caa8afa8559898df0ed5c889fa7083e"289519278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/biooncology-splash-2.swf2010-05-05T23:40:44.000Z"62b3b07135a26612ed50067173e3ecd0"415235278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/chart_3.pdf2010-05-05T23:40:48.000Z"19f06076f462f90ba38ae9b15e57d6d4"2322973278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/facingMCRC.pdf2010-05-05T23:40:59.000Z"76c0af87e5e06d9eb7381e0dabdee205"161128278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/flowplayer/flowplayer.controls.swf2010-05-05T23:41:01.000Z"0e88f2ed2b1ec37d3259a1d20ae0f5c7"26583278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/flowplayer/flowplayer.swf2010-05-05T23:41:02.000Z"f09e9408e59396dc3be7619a40b95b45"110762278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/flowplayer_$folder$2010-05-05T23:41:00.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/herceptin-slide-kit.pdf2010-05-05T23:41:12.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resource-library.swf2010-05-05T23:41:30.000Z"95b08f55818159dd23ef1d6875ad21de"24843278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/avastin/avastin-dosing.pdf2010-05-05T23:41:33.000Z"66089f8c744f9d927601afda40c77e3f"636830278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/avastin/avastin-moa-brochure.pdf2010-05-05T23:41:35.000Z"26d031dd895dad1b9aa1bd0f3750e188"1109077278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/avastin/avastin-pi.pdf2010-05-05T23:41:38.000Z"f0a86a766eea99c6db6ad3b56f0db566"306721278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/avastin/avastin-promo-pi.pdf2010-05-05T23:41:39.000Z"e00742790d858dd116cf656d8e3bb3e6"148513278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/avastin_$folder$2010-05-05T23:41:33.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/biooncology/biooncology-poster.pdf2010-05-05T23:41:40.000Z"62774dc3a1449a27be061d14307d8ac7"614488278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/biooncology/biooncology-staging-guidelines.pdf2010-05-05T23:41:41.000Z"f5eae4859ae802f9d12e72e4bbf289b5"973562278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/biooncology/biooncology-targeted-agents.pdf2010-05-05T23:41:44.000Z"1611603248eaab4cc185c75692b93874"1201993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/biooncology_$folder$2010-05-05T23:41:40.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/BCIRG_Sales_Aid_2009.pdf2010-05-05T23:41:47.000Z"2c59410871699cca7993a347dcd4e241"269942278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/HERConnections_SupportLine.pdf2010-05-05T23:42:10.000Z"49e097e35400d09c46dd4f99c83ce8cd"878418278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-adjuvant-english.pdf2010-05-05T23:41:48.000Z"8b2f5a12cdbc5b2412838362f6df8830"1528882278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-adjuvant-spanish.pdf2010-05-05T23:41:51.000Z"e14a72178efb66ccd7017e9acfd502f4"1831910278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-administration.pdf2010-05-05T23:41:54.000Z"6dd7725768b7ce46883a33646ec88aa6"377548278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-bcirg.pdf2010-05-05T23:41:56.000Z"3ccfe628504a07298cc730d0e1f988f5"75345278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-metastatic-english.pdf2010-05-05T23:41:56.000Z"9da7dfb071094ef22a0f57d05ef331fe"479992278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-metastatic-spanish.pdf2010-05-05T23:41:58.000Z"e4d595b501816084d7885e3922d0a4cc"944471278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-metastatic.pdf2010-05-05T23:41:59.000Z"09b0e10ffe011263d6deb3095826bc37"291924278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-pi.pdf2010-05-05T23:42:00.000Z"63d99938bac56e30a600cef260ff3a30"375813278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-promo-pi.pdf2010-05-05T23:42:01.000Z"52984ef23f8f06bb14b15fdb20ffa4e4"233449278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin/herceptin-slide-kit.pdf2010-05-05T23:42:02.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/herceptin_$folder$2010-05-05T23:41:46.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/menu-card/menu-card-avastin.pdf2010-05-05T23:42:12.000Z"820191f146c2cf63dde40e4a5986dcc0"724535278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/menu-card/menu-card-herceptin.pdf2010-05-05T23:42:14.000Z"8fd8258618191ee350b13b22d9279c33"753057278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/menu-card_$folder$2010-05-05T23:42:12.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/rituxan/CLL_Patient_Brochure.pdf2010-05-05T23:42:19.000Z"e2254bca4215f849888ee61b1bb4cc94"4398140278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/rituxan/rituxan-dosing.pdf2010-05-05T23:42:29.000Z"3fe93a2eb84ffd5cd6c6c20e5b78ad19"2463508278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/rituxan/rituxan-pi.pdf2010-05-05T23:42:33.000Z"60de9fc0f35c5e46cb6d74947bf4266b"209250278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/rituxan/rituxan-promo-pi.pdf2010-05-05T23:42:35.000Z"9659b0ccb1de1254c9da3aea5a61cfd8"294218278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/rituxan_$folder$2010-05-05T23:42:18.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva/Tarceva_SupportLine.pdf2010-05-05T23:42:56.000Z"47d00f9eb54a0a66d7e69cfece45d087"853788278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva/tarceva-champion-kit.pdf2010-05-05T23:42:36.000Z"d7212bc5de6d5832c2c52f2db3680e6d"1641993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva/tarceva-dosing.pdf2010-05-05T23:42:39.000Z"5acb48bd71a27a98bdc4d05c1f72f5d8"342787278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva/tarceva-nsclc-moa.pdf2010-05-05T23:42:40.000Z"e6352941a6163d46716aec3d7b768573"676096278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva/tarceva-nsclc.pdf2010-05-05T23:42:41.000Z"acf888034d84e1b8536a4ebe04055dad"421468278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva/tarceva-pc.pdf2010-05-05T23:42:43.000Z"f7753d8f13adecf268e0ee2388f0bb98"294040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva/tarceva-pi.pdf2010-05-05T23:42:44.000Z"d55b25610d0d6c57748eb5622b8443f1"2895045278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva/tarceva-promo-pi.pdf2010-05-05T23:42:49.000Z"a045dcdf5e975c4eda78dbf08019c0a3"3400035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva/tarceva-rash.pdf2010-05-05T23:42:54.000Z"c11aee7f57dd2ea52214ce92e1481514"1479745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/tarceva_$folder$2010-05-05T23:42:36.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/xeloda/xeloda-brochure.pdf2010-05-05T23:42:59.000Z"bf5e4dd5cc9f34a7dd0e15929a7cfb70"3766040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/xeloda/xeloda-dosing.pdf2010-05-05T23:43:04.000Z"ce3787c0b335eef167ee561d69f72cbb"212908278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/xeloda/xeloda-is.pdf2010-05-05T23:43:05.000Z"77f67637b3512116d005acb887631a1b"586976278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/xeloda/xeloda-moa.pdf2010-05-05T23:43:07.000Z"9601ba6c29ff03591464a445085940cf"71030278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/xeloda/xeloda-promo-pi.pdf2010-05-05T23:43:08.000Z"3966b2d3f6be8276925b466d329a8c70"5862223278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/xeloda/xeloda-support.pdf2010-05-05T23:43:17.000Z"94a8684dd01699bdc99308003037bb73"4452414278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/xeloda/xeloda-tp.pdf2010-05-05T23:43:29.000Z"76e6045c1e5358cbdb75eec5ffb3fa95"1149226278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources/xeloda_$folder$2010-05-05T23:42:58.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/resources_$folder$2010-05-05T23:41:31.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/startingTherapyWithAvastin.pdf2010-05-05T23:43:42.000Z"feb1e5f35e7b24a057c9fbe35d0a871e"600844278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/timeline/timeline.swf2010-05-05T23:44:06.000Z"d5d70aeef08bff987f8c5e8e78247b2d"114441278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/timeline/xml/timeline.xml2010-05-05T23:44:08.000Z"f1cb30b52f3f6b15b178b2284f1a0f2c"11794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/timeline/xml_$folder$2010-05-05T23:44:07.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/timeline_$folder$2010-05-05T23:44:06.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis-moa/angiogenesis_moa_animation.flv2010-05-05T23:45:24.000Z"1debdd1e7293bf3f16c0fcfc85e493c8"6855809278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis-moa/angiogenesis_moa_animation.mov2010-05-05T23:45:37.000Z"cb9b8f602e4aa016a4fbe6339db91b48"59216508278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis-moa/angiogenesis_moa_animation.wmv2010-05-05T23:48:42.000Z"c4a1664acc2ee6587fb6bb0b9b40bf21"16933637278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis-moa/config.xml2010-05-05T23:49:32.000Z"cbadd7e529b312e8f07035be327da552"298278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis-moa_$folder$2010-05-05T23:45:24.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis/VEGF_Angiogenesis_Seq1.flv2010-05-05T23:44:15.000Z"b43362e5fefda2f5a80a25cf7515cad9"5261076278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis/VEGF_Angiogenesis_Seq1.mp42010-05-05T23:44:31.000Z"d8b0763e318dd8d4fb87cdeaf1737b04"7066400278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis/VEGF_Angiogenesis_Seq1.wmv2010-05-05T23:44:53.000Z"33cee34aa04b106d60daa3ea86151d0e"8743815278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis/config.xml2010-05-05T23:44:14.000Z"79d4613d318ad18d69970787ed80e81f"285278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/angiogenesis_$folder$2010-05-05T23:44:14.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis-anim/apoptosis-anim.flv2010-05-05T23:50:20.000Z"3a15291e2aa9cdd1b3ad23c688d7e509"4881784278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis-anim/apoptosis-anim.mov2010-05-05T23:50:34.000Z"e6577f5e65da8415d1757171b9c16328"9653819278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis-anim/apoptosis-anim.wmv2010-05-05T23:51:24.000Z"fc3273a3c1bb8e96ccce9db14beaffa2"18901572278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis-anim/config.xml2010-05-05T23:53:50.000Z"21876778610577c2974351f4e4f2caeb"277278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis-anim_$folder$2010-05-05T23:50:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis/apoptosis_seq1.flv2010-05-05T23:49:33.000Z"29a365fcf88a451f0a78f200f21fce41"4423671278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis/apoptosis_seq1.mp42010-05-05T23:49:46.000Z"7ccec10b4a21c9144c3069161fd9d4b4"5858071278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis/apoptosis_seq1.wmv2010-05-05T23:50:00.000Z"daa2e188e298b9ec576281c4f484d77c"5929935278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis/config.xml2010-05-05T23:50:19.000Z"f27a7e54768b79a629a780819f12fa26"271278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/apoptosis_$folder$2010-05-05T23:49:32.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/b-cell/b-cell-animation.flv2010-05-05T23:53:51.000Z"dbc5651a0cd166766c684c48978b2c5e"6437502278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/b-cell/b-cell-animation.mov2010-05-05T23:54:06.000Z"19e5a4329fed00a85428d08a5c7436da"33059594278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/b-cell/b-cell-animation.wmv2010-05-05T23:55:36.000Z"b265921b865a5b3967f25f2f96d8444a"10165613278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/b-cell/config.xml2010-05-05T23:55:54.000Z"d3119bc31017475eb8bb67027c542270"266278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/b-cell_$folder$2010-05-05T23:53:51.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd20/cd20.flv2010-05-05T23:55:55.000Z"f22e67400b73fae60a6573896357e586"4368071278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd20/cd20.mov2010-05-05T23:56:02.000Z"4bca77970e0f6bed5b043300ff871ffa"8837933278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd20/cd20.wmv2010-05-05T23:56:26.000Z"cf2cc9e173640102471dbad0ff736d64"14901476278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd20/config.xml2010-05-05T23:57:08.000Z"4c459720bd5ab6a5a99ed3e71feb59f1"249278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd20_$folder$2010-05-05T23:55:54.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd40/cd40.flv2010-05-05T23:57:09.000Z"e2de67c7d8332f256a3ecb31b2d561a1"2686108278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd40/cd40.mov2010-05-05T23:57:15.000Z"881fb2442becfc82557a19b19aaf9a2d"5293068278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd40/cd40.wmv2010-05-05T23:57:45.000Z"99e50e1a6b08a6c53a09c68d15759ee3"9573350278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd40/config.xml2010-05-05T23:58:06.000Z"f9575e408cbb140f09af5c6114e1aba4"254278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/cd40_$folder$2010-05-05T23:57:09.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hdi/config.xml2010-05-05T23:58:07.000Z"1790a02a686fd37efcda856fc6cca54b"261278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hdi/hdi_07-26-2007.flv2010-05-05T23:58:08.000Z"564dfe5929922c9cfb6a3c9fe33f81f8"14203923278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hdi/hdi_07-26-2007.mp42010-05-05T23:58:36.000Z"f0aabf4df154e51af4a865d163fd02f3"30582286278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hdi/hdi_07-26-2007.wmv2010-05-05T23:59:31.000Z"debff5dc63bb0fe0fa777b66f3dfee3d"30675717278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hdi_$folder$2010-05-05T23:58:06.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hedgehog/config.xml2010-05-06T00:00:21.000Z"3048669f30d4de3ba5a1949b98222de8"264278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hedgehog/hedgehog.flv2010-05-06T00:00:22.000Z"311a72ea9b293fde9df0f1188478e0bb"4060037278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hedgehog/hedgehog.mov2010-05-06T00:00:28.000Z"a0b5cc8b5c2ca5096e55e97def385373"4686895278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hedgehog/hedgehog.wmv2010-05-06T00:00:37.000Z"8d703f3c6143b2327adc924c5beff1e4"15605488278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/hedgehog_$folder$2010-05-06T00:00:21.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her-pathways/config.xml2010-05-06T00:01:03.000Z"79c26547fc9fe8b4978e85a36b599a45"270278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her-pathways/her-pathways.flv2010-05-06T00:01:03.000Z"2ce983d5f8323a66bd00e8d840fb1034"2904196278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her-pathways/her-pathways.mov2010-05-06T00:01:08.000Z"75f5ab2ab5ea82540d7f605e8a6ede91"5238487278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her-pathways/her-pathways.wmv2010-05-06T00:01:16.000Z"8518ed033e9037aa57d35c827e16e6fa"13237428278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her-pathways_$folder$2010-05-06T00:01:02.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her1/config.xml2010-05-06T00:01:55.000Z"018b1e4729d281145f0f2fee4b03ae9a"262278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her1/her1-animation.flv2010-05-06T00:01:56.000Z"8ef74b03f4a98bf4832bf1bb3d9c60c5"6449826278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her1/her1-animation.mov2010-05-06T00:02:17.000Z"00d21088799c4644a20fadecfda5f609"19062358278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her1/her1-animation.wmv2010-05-06T00:02:58.000Z"f572fe34e212d22abba98cc9b413879f"4173451278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her1_$folder$2010-05-06T00:01:54.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her2/config.xml2010-05-06T00:03:06.000Z"1116374392de2f2e5dcaee2add360dad"262278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her2/her2-animation.flv2010-05-06T00:03:07.000Z"537bbffe13115ccf4c6dc426d6db9558"5819036278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her2/her2-animation.mov2010-05-06T00:03:23.000Z"7208a2c476cab0bef9d7505046acc980"49679118278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her2/her2-animation.wmv2010-05-06T00:04:23.000Z"a89981b8c3771779f7fe7f8be494c472"13805571278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/her2_$folder$2010-05-06T00:03:05.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/tdm-1/config.xml2010-05-06T00:04:39.000Z"5ee2b5d2440557f231d018b5e9b22bf1"252278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/tdm-1/tdm-1.flv2010-05-06T00:04:40.000Z"9929ff56bb17367da3479f499e54afbc"2416525278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/tdm-1/tdm-1.mov2010-05-06T00:04:44.000Z"987583207d484514724e17d6d60d3c9e"3133492278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/tdm-1/tdm-1.wmv2010-05-06T00:04:48.000Z"f4c6e90e3e323ba275550127b646e2b7"9493344278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video/tdm-1_$folder$2010-05-06T00:04:38.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505/video_$folder$2010-05-05T23:44:14.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100505_$folder$2010-05-05T23:29:50.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/AACR2007ResearchGrant.pdf2010-05-19T18:13:33.000Z"bb453042bee741c3dffbf69817824e50"434197278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ABT-263_CLL_PhaseIandIIa.pdf2010-05-19T18:13:39.000Z"bf4e38742e4f032c1011951a7f588f59"113097278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ABT-263_LymphoidMalignancies_PhaseIandIIa.pdf2010-05-19T18:13:40.000Z"6d4c5ae1e3af7a92bce40842978765cf"106391278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ABT-263_SCLCandNonHeme_PhaseIandIIa.pdf2010-05-19T18:13:40.000Z"fa3979fc907bca19db3b7ea84e5f05f8"107871278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ABT-869_BC_PhaseII.pdf2010-05-19T18:13:42.000Z"b2694519bbfd590a687bd5f53292421d"82667278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ABT_263_Phase_IIIa_US_and_Australia.pdf2010-05-19T18:13:35.000Z"cabe2174bc4a608439849c15dc77366c"50733278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ABT_263_Phase_IIIa_US_only.pdf2010-05-19T18:13:36.000Z"0146aefc4d7b578545c4be0daa483bc9"50703278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ABT_263_Phase_I_II_US_and_UK.pdf2010-05-19T18:13:34.000Z"c5fc071fd063f4ce17ceba7abcea8a70"50717278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ABT_869_Phase_II_International.pdf2010-05-19T18:13:37.000Z"95268cb5507a3c1c104c371209ce6ad6"74681278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ACRA_Hematological-Malignancies.pdf2010-05-19T18:13:45.000Z"4d5898a8fde7aa494138a3589ccdc25c"1150035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ASCO 2008 Selected Abstracts 04-25-08.xls2010-05-19T18:13:52.000Z"1966575062b9b482eb00cd4f1b5c1fa1"60416278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ASH/ASH_Abstracts_120208.xls2010-05-19T18:13:53.000Z"bb00897181b394cecf8f679471c6e21b"153088278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ASH/ASH_Abstracts_120508.xls2010-05-19T18:13:54.000Z"b600e9d9ad4cb7e98f39fbb7f3b85017"147456278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ASH_$folder$2010-05-19T18:13:53.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Apo2LTRAIL_NHL_PhaseIbandII.pdf2010-05-19T18:13:49.000Z"4983d331f6709f452b303de485e8833f"117454278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Apomab_NHL_PhaseII.pdf2010-05-19T18:13:50.000Z"e0a6351d84e901c0c383d821f8f41144"103033278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Apomab_Phase_ II_ US_and_ Australia.pdf2010-05-19T18:13:51.000Z"45d5d4e1f7743be3f996aee7fbb464bc"46794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/BIONC-21473_M05$w_DR_022504.pdf2010-05-19T18:14:13.000Z"d1775eababa6d0eef88ced7e1302b853"76791278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/BIONC22395_ASCO$ease_050604.pdf2010-05-19T18:14:14.000Z"452fa6ec5d4ede2f728c885420a604c7"67002278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Bevacizumab_ OvCa _PhaseIII.pdf2010-05-19T18:14:05.000Z"c53acb7567c265cec1ef4b1f0d619b39"115807278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Bevacizumab_BC_PhaseIII.pdf2010-05-19T18:14:06.000Z"71994c3c2a1bc1c9e4adf50f97fed9ac"108504278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Bevacizumab_CRC_PhaseIII.pdf2010-05-19T18:14:07.000Z"d3c71c6ec00b0cd18aa19ded8c23e89c"122897278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Bevacizumab_Gastric_PhaseIII.pdf2010-05-19T18:14:08.000Z"05c232f16b2241635af358f40037a427"114650278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Bevacizumab_MM_PhaseII.pdf2010-05-19T18:14:09.000Z"eb7d5af91616072826896375c1f5e2e4"98263278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Bevacizumab_NHL_PhaseIII.pdf2010-05-19T18:14:10.000Z"e3ef987c21d4fbddacc375d2f9a9954f"110462278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Bevacizumab_NSCLCandCRC_PhaseIV.pdf2010-05-19T18:14:11.000Z"b6e683f1254d466986a0aaaccb72d371"128159278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/BioOncClinicalTrials.pdf2010-05-19T18:14:15.000Z"4c404ea64308e83bc45d1cf90961871b"4365542278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Colorectal_Fact_Sheet.pdf2010-05-19T18:14:40.000Z"4334e6271e66ce373dddf1db111c6444"64260278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Erlotinib_2ndLine _NSCLC_PhaseIII.pdf2010-05-19T18:14:42.000Z"787c6e4ac294624049949406f8a5f057"121985278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Erlotinib_Adjuvant _NSCLC_PhaseIII.pdf2010-05-19T18:14:44.000Z"c2b849f0cd9fc2e6d5fd799a155f0ade"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/GDC-0449_MCRC_PhaseII.pdf2010-05-19T18:14:51.000Z"08ecc440f11351c803eaea21924409a5"121380278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/GDC-0449_OvCa_PhaseII.pdf2010-05-19T18:14:52.000Z"d5f45e8e92f095f7b5483291e40b0950"109687278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Genentech_Poster.pdf2010-05-19T18:14:53.000Z"11660522743946832ffe784c6eff94f4"226887278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/GrantApp_7_06.pdf2010-05-19T18:14:56.000Z"f2841dad3522f8e644c86b7600ae8886"526268278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Grant_AppForm2.pdf2010-05-19T18:14:55.000Z"aa9fce650a697877cf25bfbd6eb04b47"38575278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Guide_for_Interpreting_Common_Statistics_Measures_in_Clinical_Trials.pdf2010-05-19T18:14:59.000Z"b57a155f4ea1a94c5ded5538b3d749af"256334278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Hedgehog_antagonist_Phase_II_US_and_Brazil.pdf2010-05-19T18:15:00.000Z"98557d805a3aeebd43edd59f464c89ea"53875278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Hedgehog_antagonist_Phase_II_US_only.pdf2010-05-19T18:15:03.000Z"4e1e5d69a6d80e1a29577c48853a12f6"53808278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/PERTUZUMAB_Phase_III_International.pdf2010-05-19T18:15:19.000Z"aacf0161ee1a5bf19e99a3f05436a34b"82063278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/PRO131921 _Phase _III _US _only_NHL.pdf2010-05-19T18:15:20.000Z"043ecb332b03c6cd0273a04a544862d2"46688278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/PRO131921_CLL_PhaseIandII.pdf2010-05-19T18:15:21.000Z"1b9605b53efff03df8cff061277bf493"93448278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/PRO131921_NHL_PhaseIandII.pdf2010-05-19T18:15:23.000Z"1abb6719912181099018a57f808c1c2b"104609278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/PRO131921_Phase_III_US_only_CLL.pdf2010-05-19T18:15:24.000Z"7c43f92fc0b60ebe4c238878410a6062"45656278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/ResearchGrants.pdf2010-05-19T18:15:25.000Z"3f2e15d3c784cfbab58d046d7d9db491"124285278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN-40_DLBCL_PhaseIIb.pdf2010-05-19T18:18:04.000Z"8d3d17c457b4047c6359fd8e4bbce669"127122278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN-40_DLBCL_PhaseIb.pdf2010-05-19T18:18:03.000Z"2429a44660d2167c7f5749bfacff684d"100672278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN-40_MM_PhaseI.pdf2010-05-19T18:18:05.000Z"8d79ab6e9961cef45ba64c765bb07fcc"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN-40_MM_PhaseIb.pdf2010-05-19T18:18:06.000Z"0d11509f68ada61fec0069466bfea871"107612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN-40_NHL_PhaseIb.pdf2010-05-19T18:18:07.000Z"e5239c86c79906f5b30db138b62da94c"107683278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN_40_Phase_IIb_International.pdf2010-05-19T18:18:02.000Z"f4625b13c50156bb7cabb907ca2af44d"54406278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN_40_Phase_I_US_only.pdf2010-05-19T18:17:58.000Z"5821a9684051417e14915a1182c3ec5f"50387278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN_40_Phase_Ib_US_and_the_Netherlands.pdf2010-05-19T18:17:59.000Z"ec5a07a35c552dcbeef88e01d082d053"54556278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN_40_Phase_Ib_US_only_DLBCL.pdf2010-05-19T18:18:00.000Z"0366b30266534906118c90061ebe165d"52055278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/SGN_40_Phase_Ib_US_only_NHL.pdf2010-05-19T18:18:01.000Z"bfc763cbeebd124853ad7c9d413e43bc"52294278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/T-DM1_HER2+withoutpriorchemo_MBC_PhaseII.pdf2010-05-19T18:18:11.000Z"dec189454d45fdb85cd59d71da7bc6e0"111547278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/TDM-1_HER2+_MBC_PhaseII.pdf2010-05-19T18:18:26.000Z"53db40d2ac370c0658e5328f3dc3eac6"116666278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/T_DM1_Phase_II_International.pdf2010-05-19T18:18:09.000Z"6167a19d904bee16c2441e8c4bf6ea75"72554278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/T_DM1_Phase_II_US_only.pdf2010-05-19T18:18:10.000Z"f34b4a05bb808980909635a28c87c2d1"70338278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/TarcEdMat_NSCLCBrochure.pdf2010-05-19T18:18:12.000Z"fd542317d9fa1c0eaacfd5e13ed9cf9a"2981023278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/TarcEdMat_PatBrochure.pdf2010-05-19T18:18:17.000Z"8e503f3ff1d284b98bb50de3bcfed7d4"1333974278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/TarcEdMat_PatTearPad.pdf2010-05-19T18:18:20.000Z"583df506e001f03796845eab3d8c42d7"212213278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/TarcEdMat_SpocBrochure.pdf2010-05-19T18:18:21.000Z"4642065f2d99597b1f6a30a9c447bde7"1657878278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Tarceva_PI.pdf2010-05-19T18:18:24.000Z"a55b08f0fb7a47b5dd3b71caa0f50326"272502278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Trastuzumab_1stLine _MBC_PhaseIII.pdf2010-05-19T18:18:30.000Z"28752f95257c44d239395ec790719a8c"101962278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Trastuzumab_Adjuvant _BC_PhaseIII.pdf2010-05-19T18:18:31.000Z"f81e2ebc6eeba5b831add4e0d2aa66f3"120901278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/Trastuzumab_RecurrentorMetastatic _BC_PhaseIII.pdf2010-05-19T18:18:32.000Z"58805cabd72878b6b103392847230f09"105310278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/avaphysicianSlideKit.pdf2010-05-19T18:13:56.000Z"d8479650c46b6b82ab0b09f6f29c029b"1970612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/banner/biooncology-banner.swf2010-05-19T18:14:03.000Z"e4ae2aea4a6381a14f0b63d7f3fb4dc5"33568278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/banner/xml/banner.xml2010-05-19T18:14:04.000Z"6f1256045ea982ee6730aa51de5617f8"4464278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/banner/xml_$folder$2010-05-19T18:14:04.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/banner_$folder$2010-05-19T18:14:03.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/biooncology-splash-1.swf2010-05-19T18:14:29.000Z"2caa8afa8559898df0ed5c889fa7083e"289519278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/biooncology-splash-2.swf2010-05-19T18:14:31.000Z"62b3b07135a26612ed50067173e3ecd0"415235278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/chart_3.pdf2010-05-19T18:14:32.000Z"19f06076f462f90ba38ae9b15e57d6d4"2322973278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/facingMCRC.pdf2010-05-19T18:14:45.000Z"76c0af87e5e06d9eb7381e0dabdee205"161128278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/flowplayer/flowplayer.commercial-3.1.5.swf2010-07-29T00:47:27.000Z"6c946296a60f08b375858899882fdd3c"113712278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/flowplayer/flowplayer.controls-3.1.5.swf2010-07-29T00:55:30.000Z"f9aacf3d15ac150b70e828f647b844de"27007278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/flowplayer/flowplayer.controls.swf2010-05-19T18:14:47.000Z"0e88f2ed2b1ec37d3259a1d20ae0f5c7"26583278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/flowplayer/flowplayer.swf2010-05-19T18:14:48.000Z"f09e9408e59396dc3be7619a40b95b45"110762278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/flowplayer_$folder$2010-05-19T18:14:46.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/herceptin-slide-kit.pdf2010-05-19T18:15:04.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resource-library.swf2010-05-19T18:15:27.000Z"95b08f55818159dd23ef1d6875ad21de"24843278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/avastin/avastin-dosing.pdf2010-05-19T18:15:29.000Z"66089f8c744f9d927601afda40c77e3f"636830278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/avastin/avastin-moa-brochure.pdf2010-05-19T18:15:31.000Z"26d031dd895dad1b9aa1bd0f3750e188"1109077278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/avastin/avastin-pi.pdf2010-05-19T18:15:33.000Z"f0a86a766eea99c6db6ad3b56f0db566"306721278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/avastin/avastin-promo-pi.pdf2010-05-19T18:15:36.000Z"e00742790d858dd116cf656d8e3bb3e6"148513278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/avastin_$folder$2010-05-19T18:15:28.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/biooncology/biooncology-poster.pdf2010-05-19T18:15:37.000Z"62774dc3a1449a27be061d14307d8ac7"614488278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/biooncology/biooncology-staging-guidelines.pdf2010-05-19T18:15:39.000Z"f5eae4859ae802f9d12e72e4bbf289b5"973562278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/biooncology/biooncology-targeted-agents.pdf2010-05-19T18:15:42.000Z"1611603248eaab4cc185c75692b93874"1201993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/biooncology_$folder$2010-05-19T18:15:37.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/BCIRG_Sales_Aid_2009.pdf2010-05-19T18:15:46.000Z"2c59410871699cca7993a347dcd4e241"269942278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/HERConnections_SupportLine.pdf2010-05-26T22:56:17.000Z"49e097e35400d09c46dd4f99c83ce8cd"878418278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-adjuvant-english.pdf2010-05-19T18:15:48.000Z"8b2f5a12cdbc5b2412838362f6df8830"1528882278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-adjuvant-spanish.pdf2010-05-19T18:15:54.000Z"e14a72178efb66ccd7017e9acfd502f4"1831910278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-administration.pdf2010-05-19T18:16:00.000Z"6dd7725768b7ce46883a33646ec88aa6"377548278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-bcirg.pdf2010-05-19T18:16:02.000Z"3ccfe628504a07298cc730d0e1f988f5"75345278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-metastatic-english.pdf2010-05-19T18:16:03.000Z"9da7dfb071094ef22a0f57d05ef331fe"479992278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-metastatic-spanish.pdf2010-05-19T18:16:05.000Z"e4d595b501816084d7885e3922d0a4cc"944471278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-metastatic.pdf2010-05-19T18:16:10.000Z"09b0e10ffe011263d6deb3095826bc37"291924278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-pi.pdf2010-05-19T18:16:12.000Z"63d99938bac56e30a600cef260ff3a30"375813278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-promo-pi.pdf2010-05-19T18:16:17.000Z"52984ef23f8f06bb14b15fdb20ffa4e4"233449278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin/herceptin-slide-kit.pdf2010-05-19T18:16:20.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/herceptin_$folder$2010-05-19T18:15:45.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/menu-card/menu-card-avastin.pdf2010-05-19T18:16:35.000Z"820191f146c2cf63dde40e4a5986dcc0"724535278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/menu-card/menu-card-herceptin.pdf2010-05-19T18:16:37.000Z"8fd8258618191ee350b13b22d9279c33"753057278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/menu-card/menu-card-tarceva.pdf2010-05-19T18:16:40.000Z"1c051b1c88487cdb5b6b317d176306e5"721884278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/menu-card_$folder$2010-05-19T18:16:35.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/rituxan/rituxan-dosing.pdf2010-05-19T18:16:42.000Z"3fe93a2eb84ffd5cd6c6c20e5b78ad19"2463508278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/rituxan/rituxan-pi.pdf2010-05-19T18:16:47.000Z"60de9fc0f35c5e46cb6d74947bf4266b"209250278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/rituxan/rituxan-promo-pi.pdf2010-05-19T18:16:49.000Z"9659b0ccb1de1254c9da3aea5a61cfd8"294218278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/rituxan_$folder$2010-05-19T18:16:41.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva/Tarceva_SupportLine.pdf2010-05-26T23:00:27.000Z"47d00f9eb54a0a66d7e69cfece45d087"853788278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva/tarceva-champion-kit.pdf2010-05-19T18:16:53.000Z"d7212bc5de6d5832c2c52f2db3680e6d"1641993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva/tarceva-dosing.pdf2010-05-19T18:16:58.000Z"5acb48bd71a27a98bdc4d05c1f72f5d8"342787278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva/tarceva-nsclc-moa.pdf2010-05-19T18:17:02.000Z"e6352941a6163d46716aec3d7b768573"676096278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva/tarceva-nsclc.pdf2010-05-19T18:17:05.000Z"acf888034d84e1b8536a4ebe04055dad"421468278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva/tarceva-pc.pdf2010-05-19T18:17:08.000Z"f7753d8f13adecf268e0ee2388f0bb98"294040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva/tarceva-pi.pdf2010-05-19T18:17:11.000Z"d55b25610d0d6c57748eb5622b8443f1"2895045278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva/tarceva-promo-pi.pdf2010-05-19T18:17:18.000Z"a045dcdf5e975c4eda78dbf08019c0a3"3400035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva/tarceva-rash.pdf2010-05-19T18:17:24.000Z"c11aee7f57dd2ea52214ce92e1481514"1479745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/tarceva_$folder$2010-05-19T18:16:51.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/xeloda/xeloda-brochure.pdf2010-05-19T18:17:28.000Z"bf5e4dd5cc9f34a7dd0e15929a7cfb70"3766040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/xeloda/xeloda-dosing.pdf2010-05-19T18:17:38.000Z"ce3787c0b335eef167ee561d69f72cbb"212908278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/xeloda/xeloda-is.pdf2010-05-19T18:17:39.000Z"77f67637b3512116d005acb887631a1b"586976278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/xeloda/xeloda-moa.pdf2010-05-19T18:17:41.000Z"9601ba6c29ff03591464a445085940cf"71030278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/xeloda/xeloda-promo-pi.pdf2010-05-19T18:17:42.000Z"3966b2d3f6be8276925b466d329a8c70"5862223278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/xeloda/xeloda-support.pdf2010-05-19T18:17:51.000Z"94a8684dd01699bdc99308003037bb73"4452414278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/xeloda/xeloda-tp.pdf2010-05-19T18:17:56.000Z"76e6045c1e5358cbdb75eec5ffb3fa95"1149226278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources/xeloda_$folder$2010-05-19T18:17:27.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/resources_$folder$2010-05-19T18:15:28.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/startingTherapyWithAvastin.pdf2010-05-19T18:18:08.000Z"feb1e5f35e7b24a057c9fbe35d0a871e"600844278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/timeline/timeline.swf2010-05-19T18:18:27.000Z"d5d70aeef08bff987f8c5e8e78247b2d"114441278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/timeline/xml/timeline.xml2010-05-19T18:18:29.000Z"f1cb30b52f3f6b15b178b2284f1a0f2c"11794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/timeline/xml_$folder$2010-05-19T18:18:29.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/timeline_$folder$2010-05-19T18:18:27.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/Anti-NRP1/10026901_Angiogenesis_NME_NRP1.flv2010-05-20T15:56:24.000Z"9b948b14d41e6302924847ebc0cf4542"2039308278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/Anti-NRP1/config.xml2010-05-20T15:56:49.000Z"d0384df583a71475522c4e9899cad906"287278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/Anti-NRP1_$folder$2010-05-20T15:56:23.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/EGFL7/10026901_Angiogenesis_NME_EGFL7.flv2010-05-20T16:02:09.000Z"3e8d43be59fcad2dad26a6a7e412b103"7644210278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/EGFL7/config.xml2010-05-20T16:03:12.000Z"6ae78735ecc4e8f2ee89590d15adf236"280278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/EGFL7_$folder$2010-05-20T16:02:09.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GA101/10026901_B-cell_NME_GA101.flv2010-05-20T16:03:13.000Z"2b45ec3c2e5ca59a8c75864250033529"11373111278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GA101/config.xml2010-05-20T16:04:53.000Z"79ca8261f191d9f700d38052bedd6a40"274278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GA101_$folder$2010-05-20T16:03:12.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GDC-0449/10026901_Hedgehog_NME_GDC-0449.flv2010-05-20T16:04:54.000Z"98d9cf107413af83cea940e21a94d80e"2739056278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GDC-0449/config.xml2010-05-20T16:05:22.000Z"6fa628999b4ba4a47a43fbb3cf7860e3"285278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GDC-0449_$folder$2010-05-20T16:04:53.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GDC-0941/10026901_PI3K_NME_GDC-0941.flv2010-05-20T16:05:23.000Z"47aaf9bc071c8574e5f490f7901bdf1b"7642339278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GDC-0941/config.xml2010-05-20T16:06:26.000Z"404e1e4b1213e3b03205174b48da289a"281278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GDC-0941_$folder$2010-05-20T16:05:22.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GDC-0973/10026901_MEK_NME_GDC-0973.flv2010-05-20T16:06:28.000Z"ea7db5a56355fe58c1ca1aa0d2533c7c"6349838278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GDC-0973/config.xml2010-05-20T16:07:21.000Z"fdba6af38ccb9f28b98c53c7cf963563"280278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/GDC-0973_$folder$2010-05-20T16:06:27.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/HER/10026901_HER_Signaling.flv2010-05-20T16:09:36.000Z"f7b1802dad26abb45c60c49ea5e39aef"6033142278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/HER/config.xml2010-05-20T16:10:32.000Z"a9b9f32fd02521933245fba386c17b95"267278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/HER_$folder$2010-05-20T16:09:35.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/MEK/10026901_MEK_Signaling.flv2010-05-20T16:10:34.000Z"3d947f0af84a584ef773359c54006e0a"7126227278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/MEK/config.xml2010-05-20T16:11:32.000Z"fe328022d7653f01a2f669e442103aea"267278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/MEK_$folder$2010-05-20T16:10:33.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/PI3K/10026901_PI3K_Signaling.flv2010-05-20T16:14:20.000Z"61d33689cea0383f1c4dd6c1e7784946"4899713278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/PI3K/config.xml2010-05-20T16:15:13.000Z"d4f29145c502070f426c9349f6ef00fc"270278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/PI3K_$folder$2010-05-20T16:14:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/RG7204/10323400_BRAF_NME_RG7204.flv2010-05-20T16:15:14.000Z"078132aa5ee334647fe21b096994832b"878457278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/RG7204/config.xml2010-05-20T16:15:26.000Z"7142f5ef5644411544736a7bbbf29e73"275278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/RG7204_$folder$2010-05-20T16:15:14.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/T-DM1/TDM1.flv2010-05-20T16:15:28.000Z"cd61d1a31e6524e934fdbfdcc616b1d2"3962165278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/T-DM1/config.xml2010-05-20T16:15:27.000Z"3a110bbd18d962d69d1178b6d8becdc9"253278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/T-DM1_$folder$2010-05-20T16:15:27.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/angiogenesis/10026901_Angiogenesis.flv2010-05-20T15:55:14.000Z"071a30c8c760ed4dde592b9aab453bdf"9154894278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/angiogenesis/config.xml2010-05-20T15:56:22.000Z"afb381ae0b40bbb1e8c513fd23e61486"284278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/angiogenesis_$folder$2010-05-20T15:54:49.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/apomab/Apomab.flv2010-05-20T15:56:50.000Z"c8ce69d36309dfa9edc5fcaa0ddf0f2d"7007481278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/apomab_$folder$2010-05-20T15:56:50.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/apoptosis/10026901_Apoptotic_Pathways.flv2010-05-20T15:57:37.000Z"91346f2378f12b61ccc4ca015fec221c"8718182278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/apoptosis/config.xml2010-05-20T15:58:50.000Z"b35217a3183659ed7400073f802452b7"284278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/apoptosis_$folder$2010-05-20T15:57:37.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/bcell/10323400_B-cell_Surface_Proteins.flv2010-05-20T15:58:52.000Z"b90cf9685a693a6049eae6bcf75e0b67"1325715278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/bcell/config.xml2010-05-20T15:59:06.000Z"85215ef11322ac0ec522f4a67e65e102"281278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/bcell_$folder$2010-05-20T15:58:51.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/braf_moa/10201700_BRAF_MOA_VO.flv2010-05-20T15:59:07.000Z"944b53f3f95b0b354b34c4991e92bdec"10790886278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/braf_moa/config.xml2010-05-20T16:00:40.000Z"761bc30afed0015c0bbe7973a3d86cdc"275278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/braf_moa_$folder$2010-05-20T15:59:06.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/braf_pathway/10323400_BRAF_Pathway.flv2010-05-20T16:00:41.000Z"fdb08d5d0300f07d031237f2c4d07460"1773804278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/braf_pathway/config.xml2010-05-20T16:01:03.000Z"7f396fc73e1611e0e1a5ce7127ab1c6c"284278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/braf_pathway_$folder$2010-05-20T16:00:41.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/dacetuzumab/Dacetuzumab.flv2010-05-20T16:01:06.000Z"89016fe528d46bd6f1c0702935357d38"4725259278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/dacetuzumab/config.xml2010-05-20T16:01:05.000Z"55bbb27d7501d9d7485279a558bfb0a6"272278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/dacetuzumab_$folder$2010-05-20T16:01:04.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/dulanermin/10026901_Apoptosis_NME_Dulanermin.flv2010-05-20T16:01:48.000Z"495e2b8892aa6b09b8db50f7b962777e"2442180278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/dulanermin/config.xml2010-05-20T16:02:08.000Z"725084177622dbae3cfcf3d5f977e897"292278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/dulanermin_$folder$2010-05-20T16:01:47.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/hedgehog/10026901_Hedgehog_Signaling.flv2010-05-20T16:07:22.000Z"4c8f6094142cfcc593d1b551ae4b0ad2"14559106278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/hedgehog/config.xml2010-05-20T16:09:34.000Z"d560f599a8ce275c0f8e6ade0101056c"282278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/hedgehog_$folder$2010-05-20T16:07:22.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/met-signaling/10026901_Met_Signaling.flv2010-05-20T16:11:33.000Z"ce467f99049c48f8545977fec994d5a4"8010273278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/met-signaling/config.xml2010-05-20T16:12:43.000Z"27d0e7d77fb25cb65fea25d12e7234fd"286278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/met-signaling_$folder$2010-05-20T16:11:33.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/metmab/10026901_Met_MetMAb.flv2010-05-20T16:12:44.000Z"4167e265a12656dfb1e04ca7f2aa256d"2787196278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/metmab/config.xml2010-05-20T16:13:20.000Z"9ba68cb7fb1633193dd91abc86752f9c"270278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/metmab_$folder$2010-05-20T16:12:43.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/navitoclax/10323400_Apoptosis_NME_Navitoclax.flv2010-05-20T16:13:22.000Z"2df53b36bbea683e5efd102441aed7c0"2420814278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/navitoclax/config.xml2010-05-20T16:13:39.000Z"0b60f6760de76c0ca50f5e4d86913a6a"292278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/navitoclax_$folder$2010-05-20T16:13:21.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/pertuzumab/10026901_HER_Pertuzumab.flv2010-05-20T16:13:40.000Z"dfdb0e63a551062c9031ae2b82426c6f"2689175278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/pertuzumab/config.xml2010-05-20T16:14:19.000Z"c209f7761edb14640c5a1d0137accf41"282278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/pertuzumab_$folder$2010-05-20T16:13:39.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video/player_$folder$2010-05-20T16:15:13.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519/video_$folder$2010-05-20T15:54:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100519_$folder$2010-05-19T18:11:51.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100728_$folder$2010-07-29T00:46:30.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820/10382400_BRAF_MOA.pptx2010-08-20T15:07:50.000Z"a86bd4810d8ee0b069e1f975e21f45ba"465029278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820/Angiogenesis-SlideKit.ppt2010-08-20T15:07:52.000Z"bf428ea6c1b09f901351ba5111408ba5"1437184278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820/Apoptosis-SlideKit.ppt2010-08-20T15:07:54.000Z"491b6aae050a63d8453313db3b92c134"3163136278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820/Avastin-MCC-Pat-Brochure.pdf2010-08-20T15:07:57.000Z"c239d8dd1fe3c6f9fc5fdced2db6649b"1541932278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820/Avastin-NCCL-Pat-Brochure.pdf2010-08-20T15:08:00.000Z"4f65b5b7d44c013b6861ce2de4795b56"1644006278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820/Avastin-Support-Line.pdf2010-08-20T15:08:02.000Z"73174ac2995adf520f37778ead8d5d32"116982278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820/Biooncology-FlashCard.pdf2010-08-20T15:08:02.000Z"d433440a34136328e84f3dfecf5909d1"722566278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820/Biooncology-SlideKit.ppt2010-08-20T15:08:04.000Z"17ce1cfd8d8a6d823ce975b956e3fbbd"8821760278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820/Pathways_Slide_Deck_final.ppt2010-08-20T15:08:12.000Z"3b3dff4d14c1d547d00919dff06302d3"3949568278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20100820_$folder$2010-08-20T15:07:18.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/AACR2007ResearchGrant.pdf2010-10-22T18:02:14.000Z"bb453042bee741c3dffbf69817824e50"434197278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ABT-263_CLL_PhaseIandIIa.pdf2010-10-22T18:02:15.000Z"bf4e38742e4f032c1011951a7f588f59"113097278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ABT-263_LymphoidMalignancies_PhaseIandIIa.pdf2010-10-22T18:02:15.000Z"6d4c5ae1e3af7a92bce40842978765cf"106391278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ABT-263_SCLCandNonHeme_PhaseIandIIa.pdf2010-10-22T18:02:16.000Z"fa3979fc907bca19db3b7ea84e5f05f8"107871278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ABT-869_BC_PhaseII.pdf2010-10-22T18:02:16.000Z"b2694519bbfd590a687bd5f53292421d"82667278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ABT_263_Phase_IIIa_US_and_Australia.pdf2010-10-22T18:02:17.000Z"cabe2174bc4a608439849c15dc77366c"50733278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ABT_263_Phase_IIIa_US_only.pdf2010-10-22T18:02:17.000Z"0146aefc4d7b578545c4be0daa483bc9"50703278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ABT_263_Phase_I_II_US_and_UK.pdf2010-10-22T18:02:17.000Z"c5fc071fd063f4ce17ceba7abcea8a70"50717278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ABT_869_Phase_II_International.pdf2010-10-22T18:02:18.000Z"95268cb5507a3c1c104c371209ce6ad6"74681278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ACRA_Hematological-Malignancies.pdf2010-10-22T18:02:19.000Z"4d5898a8fde7aa494138a3589ccdc25c"1150035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ASCO 2008 Selected Abstracts 04-25-08.xls2010-10-22T18:02:20.000Z"1966575062b9b482eb00cd4f1b5c1fa1"60416278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ASH/ASH_Abstracts_120208.xls2010-10-22T18:00:13.000Z"bb00897181b394cecf8f679471c6e21b"153088278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ASH/ASH_Abstracts_120508.xls2010-10-22T18:00:13.000Z"b600e9d9ad4cb7e98f39fbb7f3b85017"147456278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ASH_$folder$2010-10-22T18:00:13.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Apo2LTRAIL_NHL_PhaseIbandII.pdf2010-10-22T18:02:20.000Z"4983d331f6709f452b303de485e8833f"117454278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Apomab_NHL_PhaseII.pdf2010-10-22T18:02:21.000Z"e0a6351d84e901c0c383d821f8f41144"103033278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Apomab_Phase_ II_ US_and_ Australia.pdf2010-10-22T18:02:21.000Z"45d5d4e1f7743be3f996aee7fbb464bc"46794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/BIONC-21473_M05$w_DR_022504.pdf2010-10-22T18:02:22.000Z"d1775eababa6d0eef88ced7e1302b853"76791278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/BIONC22395_ASCO$ease_050604.pdf2010-10-22T18:02:22.000Z"452fa6ec5d4ede2f728c885420a604c7"67002278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Bevacizumab_ OvCa _PhaseIII.pdf2010-10-22T18:02:23.000Z"c53acb7567c265cec1ef4b1f0d619b39"115807278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Bevacizumab_BC_PhaseIII.pdf2010-10-22T18:02:24.000Z"71994c3c2a1bc1c9e4adf50f97fed9ac"108504278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Bevacizumab_CRC_PhaseIII.pdf2010-10-22T18:02:24.000Z"d3c71c6ec00b0cd18aa19ded8c23e89c"122897278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Bevacizumab_Gastric_PhaseIII.pdf2010-10-22T18:02:25.000Z"05c232f16b2241635af358f40037a427"114650278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Bevacizumab_MM_PhaseII.pdf2010-10-22T18:02:25.000Z"eb7d5af91616072826896375c1f5e2e4"98263278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Bevacizumab_NHL_PhaseIII.pdf2010-10-22T18:02:26.000Z"e3ef987c21d4fbddacc375d2f9a9954f"110462278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Bevacizumab_NSCLCandCRC_PhaseIV.pdf2010-10-22T18:02:27.000Z"b6e683f1254d466986a0aaaccb72d371"128159278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/BioOncClinicalTrials.pdf2010-10-22T18:02:28.000Z"4c404ea64308e83bc45d1cf90961871b"4365542278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Colorectal_Fact_Sheet.pdf2010-10-22T18:02:30.000Z"4334e6271e66ce373dddf1db111c6444"64260278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Erlotinib_2ndLine _NSCLC_PhaseIII.pdf2010-10-22T18:02:30.000Z"787c6e4ac294624049949406f8a5f057"121985278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Erlotinib_Adjuvant _NSCLC_PhaseIII.pdf2010-10-22T18:02:31.000Z"c2b849f0cd9fc2e6d5fd799a155f0ade"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/GDC-0449_MCRC_PhaseII.pdf2010-10-22T18:02:31.000Z"08ecc440f11351c803eaea21924409a5"121380278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/GDC-0449_OvCa_PhaseII.pdf2010-10-22T18:02:32.000Z"d5f45e8e92f095f7b5483291e40b0950"109687278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Genentech_Poster.pdf2010-10-22T18:02:33.000Z"11660522743946832ffe784c6eff94f4"226887278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/GrantApp_7_06.pdf2010-10-22T18:02:33.000Z"f2841dad3522f8e644c86b7600ae8886"526268278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Grant_AppForm2.pdf2010-10-22T18:02:34.000Z"aa9fce650a697877cf25bfbd6eb04b47"38575278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Guide_for_Interpreting_Common_Statistics_Measures_in_Clinical_Trials.pdf2010-10-22T18:02:35.000Z"b57a155f4ea1a94c5ded5538b3d749af"256334278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Hedgehog_antagonist_Phase_II_US_and_Brazil.pdf2010-10-22T18:02:36.000Z"98557d805a3aeebd43edd59f464c89ea"53875278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Hedgehog_antagonist_Phase_II_US_only.pdf2010-10-22T18:02:36.000Z"4e1e5d69a6d80e1a29577c48853a12f6"53808278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/PERTUZUMAB_Phase_III_International.pdf2010-10-22T18:02:37.000Z"aacf0161ee1a5bf19e99a3f05436a34b"82063278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/PRO131921 _Phase _III _US _only_NHL.pdf2010-10-22T18:02:37.000Z"043ecb332b03c6cd0273a04a544862d2"46688278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/PRO131921_CLL_PhaseIandII.pdf2010-10-22T18:02:38.000Z"1b9605b53efff03df8cff061277bf493"93448278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/PRO131921_NHL_PhaseIandII.pdf2010-10-22T18:02:38.000Z"1abb6719912181099018a57f808c1c2b"104609278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/PRO131921_Phase_III_US_only_CLL.pdf2010-10-22T18:02:39.000Z"7c43f92fc0b60ebe4c238878410a6062"45656278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/ResearchGrants.pdf2010-10-22T18:02:39.000Z"3f2e15d3c784cfbab58d046d7d9db491"124285278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN-40_DLBCL_PhaseIIb.pdf2010-10-22T18:02:40.000Z"8d3d17c457b4047c6359fd8e4bbce669"127122278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN-40_DLBCL_PhaseIb.pdf2010-10-22T18:02:40.000Z"2429a44660d2167c7f5749bfacff684d"100672278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN-40_MM_PhaseI.pdf2010-10-22T18:02:41.000Z"8d79ab6e9961cef45ba64c765bb07fcc"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN-40_MM_PhaseIb.pdf2010-10-22T18:02:41.000Z"0d11509f68ada61fec0069466bfea871"107612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN-40_NHL_PhaseIb.pdf2010-10-22T18:02:42.000Z"e5239c86c79906f5b30db138b62da94c"107683278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN_40_Phase_IIb_International.pdf2010-10-22T18:02:43.000Z"f4625b13c50156bb7cabb907ca2af44d"54406278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN_40_Phase_I_US_only.pdf2010-10-22T18:02:45.000Z"5821a9684051417e14915a1182c3ec5f"50387278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN_40_Phase_Ib_US_and_the_Netherlands.pdf2010-10-22T18:02:46.000Z"ec5a07a35c552dcbeef88e01d082d053"54556278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN_40_Phase_Ib_US_only_DLBCL.pdf2010-10-22T18:02:46.000Z"0366b30266534906118c90061ebe165d"52055278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/SGN_40_Phase_Ib_US_only_NHL.pdf2010-10-22T18:02:47.000Z"bfc763cbeebd124853ad7c9d413e43bc"52294278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Tarceva_PI.pdf2010-10-22T00:48:31.000Z"a55b08f0fb7a47b5dd3b71caa0f50326"272502278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Trastuzumab_1stLine _MBC_PhaseIII.pdf2010-10-22T00:48:31.000Z"28752f95257c44d239395ec790719a8c"101962278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Trastuzumab_Adjuvant _BC_PhaseIII.pdf2010-10-22T00:48:31.000Z"f81e2ebc6eeba5b831add4e0d2aa66f3"120901278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/Trastuzumab_RecurrentorMetastatic _BC_PhaseIII.pdf2010-10-22T00:48:32.000Z"58805cabd72878b6b103392847230f09"105310278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/avaphysicianSlideKit.pdf2010-10-22T00:48:32.000Z"d8479650c46b6b82ab0b09f6f29c029b"1970612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/banner/biooncology-banner.swf2010-10-22T17:59:43.000Z"e4ae2aea4a6381a14f0b63d7f3fb4dc5"33568278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/banner/xml/banner.xml2010-10-22T17:59:44.000Z"6f1256045ea982ee6730aa51de5617f8"4464278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/banner/xml_$folder$2010-10-22T17:59:44.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/banner_$folder$2010-10-22T17:59:43.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/biooncology-splash-1.swf2010-10-22T18:03:35.000Z"2caa8afa8559898df0ed5c889fa7083e"289519278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/biooncology-splash-2.swf2010-10-22T18:03:36.000Z"62b3b07135a26612ed50067173e3ecd0"415235278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/chart_3.pdf2010-10-22T18:03:37.000Z"19f06076f462f90ba38ae9b15e57d6d4"2322973278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/facingMCRC.pdf2010-10-22T18:03:38.000Z"76c0af87e5e06d9eb7381e0dabdee205"161128278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/flowplayer/flowplayer.commercial-3.1.5.swf2010-10-22T18:00:30.000Z"6c946296a60f08b375858899882fdd3c"113712278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/flowplayer/flowplayer.controls-3.1.5.swf2010-10-22T18:00:30.000Z"f9aacf3d15ac150b70e828f647b844de"27007278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/flowplayer/flowplayer.controls.swf2010-10-22T18:00:30.000Z"0e88f2ed2b1ec37d3259a1d20ae0f5c7"26583278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/flowplayer/flowplayer.swf2010-10-22T18:00:31.000Z"f09e9408e59396dc3be7619a40b95b45"110762278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/flowplayer_$folder$2010-10-22T18:00:29.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/herceptin-slide-kit.pdf2010-10-22T18:03:39.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resource-library.swf2010-10-22T18:03:40.000Z"95b08f55818159dd23ef1d6875ad21de"24843278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/avastin/avastin-dosing.pdf2010-10-22T18:00:49.000Z"66089f8c744f9d927601afda40c77e3f"636830278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/avastin/avastin-moa-brochure.pdf2010-10-22T18:00:49.000Z"26d031dd895dad1b9aa1bd0f3750e188"1109077278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/avastin/avastin-pi.pdf2010-10-22T18:00:50.000Z"f0a86a766eea99c6db6ad3b56f0db566"306721278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/avastin/avastin-promo-pi.pdf2010-10-22T18:00:50.000Z"e00742790d858dd116cf656d8e3bb3e6"148513278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/avastin_$folder$2010-10-22T18:00:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/biooncology/biooncology-poster.pdf2010-10-22T18:00:52.000Z"62774dc3a1449a27be061d14307d8ac7"614488278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/biooncology/biooncology-staging-guidelines.pdf2010-10-22T18:00:52.000Z"f5eae4859ae802f9d12e72e4bbf289b5"973562278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/biooncology/biooncology-targeted-agents.pdf2010-10-22T18:00:53.000Z"1611603248eaab4cc185c75692b93874"1201993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/biooncology_$folder$2010-10-22T18:00:51.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/BCIRG_Sales_Aid_2009.pdf2010-10-22T18:00:54.000Z"2c59410871699cca7993a347dcd4e241"269942278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/HERConnections_SupportLine.pdf2010-10-22T18:00:55.000Z"49e097e35400d09c46dd4f99c83ce8cd"878418278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-adjuvant-english.pdf2010-10-22T18:00:55.000Z"8b2f5a12cdbc5b2412838362f6df8830"1528882278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-adjuvant-spanish.pdf2010-10-22T18:00:56.000Z"e14a72178efb66ccd7017e9acfd502f4"1831910278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-administration.pdf2010-10-22T18:00:56.000Z"6dd7725768b7ce46883a33646ec88aa6"377548278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-bcirg.pdf2010-10-22T18:00:57.000Z"3ccfe628504a07298cc730d0e1f988f5"75345278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-metastatic-english.pdf2010-10-22T18:00:57.000Z"9da7dfb071094ef22a0f57d05ef331fe"479992278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-metastatic-spanish.pdf2010-10-22T18:00:58.000Z"e4d595b501816084d7885e3922d0a4cc"944471278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-metastatic.pdf2010-10-22T18:00:58.000Z"09b0e10ffe011263d6deb3095826bc37"291924278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-pi.pdf2010-10-22T18:00:59.000Z"63d99938bac56e30a600cef260ff3a30"375813278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-promo-pi.pdf2010-10-22T18:01:00.000Z"52984ef23f8f06bb14b15fdb20ffa4e4"233449278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin/herceptin-slide-kit.pdf2010-10-22T18:01:00.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/herceptin_$folder$2010-10-22T18:00:54.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/menu-card/menu-card-avastin.pdf2010-10-22T18:01:02.000Z"820191f146c2cf63dde40e4a5986dcc0"724535278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/menu-card/menu-card-herceptin.pdf2010-10-22T18:01:02.000Z"8fd8258618191ee350b13b22d9279c33"753057278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/menu-card/menu-card-tarceva.pdf2010-10-22T18:01:03.000Z"1c051b1c88487cdb5b6b317d176306e5"721884278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/menu-card_$folder$2010-10-22T18:01:01.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/rituxan/rituxan-dosing.pdf2010-10-22T18:01:04.000Z"3fe93a2eb84ffd5cd6c6c20e5b78ad19"2463508278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/rituxan/rituxan-pi.pdf2010-10-22T18:01:05.000Z"60de9fc0f35c5e46cb6d74947bf4266b"209250278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/rituxan/rituxan-promo-pi.pdf2010-10-22T18:01:05.000Z"9659b0ccb1de1254c9da3aea5a61cfd8"294218278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/rituxan_$folder$2010-10-22T18:01:03.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva/Tarceva_SupportLine.pdf2010-10-22T18:01:07.000Z"47d00f9eb54a0a66d7e69cfece45d087"853788278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva/tarceva-champion-kit.pdf2010-10-22T18:01:07.000Z"d7212bc5de6d5832c2c52f2db3680e6d"1641993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva/tarceva-dosing.pdf2010-10-22T18:01:08.000Z"5acb48bd71a27a98bdc4d05c1f72f5d8"342787278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva/tarceva-nsclc-moa.pdf2010-10-22T18:01:09.000Z"e6352941a6163d46716aec3d7b768573"676096278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva/tarceva-nsclc.pdf2010-10-22T18:01:09.000Z"acf888034d84e1b8536a4ebe04055dad"421468278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva/tarceva-pc.pdf2010-10-22T18:01:10.000Z"f7753d8f13adecf268e0ee2388f0bb98"294040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva/tarceva-pi.pdf2010-10-22T18:01:10.000Z"d55b25610d0d6c57748eb5622b8443f1"2895045278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva/tarceva-promo-pi.pdf2010-10-22T18:01:11.000Z"a045dcdf5e975c4eda78dbf08019c0a3"3400035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva/tarceva-rash.pdf2010-10-22T18:01:11.000Z"c11aee7f57dd2ea52214ce92e1481514"1479745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/tarceva_$folder$2010-10-22T18:01:06.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/xeloda/xeloda-brochure.pdf2010-10-22T18:01:12.000Z"bf5e4dd5cc9f34a7dd0e15929a7cfb70"3766040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/xeloda/xeloda-dosing.pdf2010-10-22T18:01:13.000Z"ce3787c0b335eef167ee561d69f72cbb"212908278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/xeloda/xeloda-is.pdf2010-10-22T18:01:13.000Z"77f67637b3512116d005acb887631a1b"586976278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/xeloda/xeloda-moa.pdf2010-10-22T18:01:13.000Z"9601ba6c29ff03591464a445085940cf"71030278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/xeloda/xeloda-promo-pi.pdf2010-10-22T18:01:14.000Z"3966b2d3f6be8276925b466d329a8c70"5862223278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/xeloda/xeloda-support.pdf2010-10-22T18:01:16.000Z"94a8684dd01699bdc99308003037bb73"4452414278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/xeloda/xeloda-tp.pdf2010-10-22T18:01:17.000Z"76e6045c1e5358cbdb75eec5ffb3fa95"1149226278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources/xeloda_$folder$2010-10-22T18:01:12.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/resources_$folder$2010-10-22T18:00:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/startingTherapyWithAvastin.pdf2010-10-22T18:03:40.000Z"feb1e5f35e7b24a057c9fbe35d0a871e"600844278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/timeline/timeline.swf2010-10-22T18:01:33.000Z"d5d70aeef08bff987f8c5e8e78247b2d"114441278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/timeline/xml/timeline.xml2010-10-22T18:01:34.000Z"f1cb30b52f3f6b15b178b2284f1a0f2c"11794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/timeline/xml_$folder$2010-10-22T18:01:34.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/timeline_$folder$2010-10-22T18:01:33.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/Anti-NRP1/10026901_Angiogenesis_NME_NRP1.flv2010-10-22T17:53:16.000Z"9b948b14d41e6302924847ebc0cf4542"2039308278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/Anti-NRP1/config.xml2010-10-22T17:53:17.000Z"d0384df583a71475522c4e9899cad906"287278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/Anti-NRP1_$folder$2010-10-22T17:53:16.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/EGFL7/10026901_Angiogenesis_NME_EGFL7.flv2010-10-22T17:53:17.000Z"3e8d43be59fcad2dad26a6a7e412b103"7644210278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/EGFL7/config.xml2010-10-22T17:53:18.000Z"6ae78735ecc4e8f2ee89590d15adf236"280278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/EGFL7_$folder$2010-10-22T17:53:17.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GA101/10026901_B-cell_NME_GA101.flv2010-10-22T17:53:19.000Z"2b45ec3c2e5ca59a8c75864250033529"11373111278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GA101/config.xml2010-10-22T17:53:20.000Z"79ca8261f191d9f700d38052bedd6a40"274278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GA101_$folder$2010-10-22T17:53:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GDC-0449/10026901_Hedgehog_NME_GDC-0449.flv2010-10-22T17:53:20.000Z"98d9cf107413af83cea940e21a94d80e"2739056278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GDC-0449/config.xml2010-10-22T17:53:21.000Z"6fa628999b4ba4a47a43fbb3cf7860e3"285278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GDC-0449_$folder$2010-10-22T17:53:20.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GDC-0941/10026901_PI3K_NME_GDC-0941.flv2010-10-22T17:53:22.000Z"47aaf9bc071c8574e5f490f7901bdf1b"7642339278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GDC-0941/config.xml2010-10-22T17:53:22.000Z"404e1e4b1213e3b03205174b48da289a"281278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GDC-0941_$folder$2010-10-22T17:53:21.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GDC-0973/10026901_MEK_NME_GDC-0973.flv2010-10-22T17:53:23.000Z"ea7db5a56355fe58c1ca1aa0d2533c7c"6349838278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GDC-0973/config.xml2010-10-22T17:53:24.000Z"fdba6af38ccb9f28b98c53c7cf963563"280278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/GDC-0973_$folder$2010-10-22T17:53:23.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/HER/10026901_HER_Signaling.flv2010-10-22T17:53:25.000Z"f7b1802dad26abb45c60c49ea5e39aef"6033142278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/HER/config.xml2010-10-22T17:53:26.000Z"a9b9f32fd02521933245fba386c17b95"267278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/HER_$folder$2010-10-22T17:53:25.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/MEK/10026901_MEK_Signaling.flv2010-10-22T17:53:27.000Z"3d947f0af84a584ef773359c54006e0a"7126227278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/MEK/config.xml2010-10-22T17:53:27.000Z"fe328022d7653f01a2f669e442103aea"267278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/MEK_$folder$2010-10-22T17:53:26.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/PI3K/10026901_PI3K_Signaling.flv2010-10-22T17:53:28.000Z"61d33689cea0383f1c4dd6c1e7784946"4899713278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/PI3K/config.xml2010-10-22T17:53:29.000Z"d4f29145c502070f426c9349f6ef00fc"270278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/PI3K_$folder$2010-10-22T17:53:28.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/RG7204/10323400_BRAF_NME_RG7204.flv2010-10-22T17:53:30.000Z"078132aa5ee334647fe21b096994832b"878457278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/RG7204/config.xml2010-10-22T17:53:31.000Z"7142f5ef5644411544736a7bbbf29e73"275278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/RG7204_$folder$2010-10-22T17:53:30.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/T-DM1/TDM1.flv2010-10-22T17:53:31.000Z"cd61d1a31e6524e934fdbfdcc616b1d2"3962165278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/T-DM1/config.xml2010-10-22T17:53:32.000Z"3a110bbd18d962d69d1178b6d8becdc9"253278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/T-DM1_$folder$2010-10-22T17:53:31.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/angiogenesis/10026901_Angiogenesis.flv2010-10-22T17:53:33.000Z"071a30c8c760ed4dde592b9aab453bdf"9154894278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/angiogenesis/config.xml2010-10-22T17:53:34.000Z"afb381ae0b40bbb1e8c513fd23e61486"284278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/angiogenesis_$folder$2010-10-22T17:53:33.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/apomab/Apomab.flv2010-10-22T17:53:36.000Z"c8ce69d36309dfa9edc5fcaa0ddf0f2d"7007481278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/apomab_$folder$2010-10-22T17:53:35.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/apoptosis/10026901_Apoptotic_Pathways.flv2010-10-22T17:53:38.000Z"91346f2378f12b61ccc4ca015fec221c"8718182278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/apoptosis/config.xml2010-10-22T17:53:40.000Z"b35217a3183659ed7400073f802452b7"284278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/apoptosis_$folder$2010-10-22T17:53:37.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/bcell/10323400_B-cell_Surface_Proteins.flv2010-10-22T17:53:41.000Z"b90cf9685a693a6049eae6bcf75e0b67"1325715278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/bcell/config.xml2010-10-22T17:53:42.000Z"85215ef11322ac0ec522f4a67e65e102"281278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/bcell_$folder$2010-10-22T17:53:40.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/braf_moa/10201701_BRAF_VO_MOA.flv2010-10-23T00:20:36.000Z"a788757a76b6e38cf88885d61cfbd1b4"29999771278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/braf_moa/config.xml2010-10-28T21:46:20.000Z"edb4fa2ce462c0bed1ada652e0378c09"275278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/braf_moa_$folder$2010-10-22T17:53:42.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/braf_pathway/10323400_BRAF_Pathway.flv2010-10-22T17:53:45.000Z"fdb08d5d0300f07d031237f2c4d07460"1773804278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/braf_pathway/config.xml2010-10-22T17:53:46.000Z"7f396fc73e1611e0e1a5ce7127ab1c6c"284278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/braf_pathway_$folder$2010-10-22T17:53:44.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/dacetuzumab/Dacetuzumab.flv2010-10-22T17:53:47.000Z"89016fe528d46bd6f1c0702935357d38"4725259278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/dacetuzumab/config.xml2010-10-22T17:53:47.000Z"55bbb27d7501d9d7485279a558bfb0a6"272278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/dacetuzumab_$folder$2010-10-22T17:53:46.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/dulanermin/10026901_Apoptosis_NME_Dulanermin.flv2010-10-22T17:53:48.000Z"495e2b8892aa6b09b8db50f7b962777e"2442180278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/dulanermin/config.xml2010-10-22T17:53:49.000Z"725084177622dbae3cfcf3d5f977e897"292278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/dulanermin_$folder$2010-10-22T17:53:48.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/hedgehog/10026901_Hedgehog_Signaling.flv2010-10-22T17:53:50.000Z"4c8f6094142cfcc593d1b551ae4b0ad2"14559106278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/hedgehog/config.xml2010-10-22T17:53:51.000Z"d560f599a8ce275c0f8e6ade0101056c"282278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/hedgehog_$folder$2010-10-22T17:53:49.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/met-signaling/10026901_Met_Signaling.flv2010-10-22T17:53:52.000Z"ce467f99049c48f8545977fec994d5a4"8010273278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/met-signaling/config.xml2010-10-22T17:53:56.000Z"27d0e7d77fb25cb65fea25d12e7234fd"286278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/met-signaling_$folder$2010-10-22T17:53:52.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/metmab/10026901_Met_MetMAb.flv2010-10-22T17:53:57.000Z"4167e265a12656dfb1e04ca7f2aa256d"2787196278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/metmab/config.xml2010-10-22T17:53:57.000Z"9ba68cb7fb1633193dd91abc86752f9c"270278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/metmab_$folder$2010-10-22T17:53:56.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/navitoclax/10323400_Apoptosis_NME_Navitoclax.flv2010-10-22T17:53:58.000Z"2df53b36bbea683e5efd102441aed7c0"2420814278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/navitoclax/config.xml2010-10-22T17:53:59.000Z"0b60f6760de76c0ca50f5e4d86913a6a"292278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/navitoclax_$folder$2010-10-22T17:53:57.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/pertuzumab/10026901_HER_Pertuzumab.flv2010-10-22T17:53:59.000Z"dfdb0e63a551062c9031ae2b82426c6f"2689175278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/pertuzumab/config.xml2010-10-22T17:54:00.000Z"c209f7761edb14640c5a1d0137accf41"282278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/pertuzumab_$folder$2010-10-22T17:53:59.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video/player_$folder$2010-10-22T17:54:00.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021/video_$folder$2010-10-22T17:53:15.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20101021_$folder$2010-10-22T00:43:05.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/AACR2007ResearchGrant.pdf2011-01-06T18:58:26.000Z"bb453042bee741c3dffbf69817824e50"434197278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ABT-263_CLL_PhaseIandIIa.pdf2011-01-06T18:58:27.000Z"bf4e38742e4f032c1011951a7f588f59"113097278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ABT-263_LymphoidMalignancies_PhaseIandIIa.pdf2011-01-06T18:58:27.000Z"6d4c5ae1e3af7a92bce40842978765cf"106391278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ABT-263_SCLCandNonHeme_PhaseIandIIa.pdf2011-01-06T18:58:28.000Z"fa3979fc907bca19db3b7ea84e5f05f8"107871278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ABT-869_BC_PhaseII.pdf2011-01-06T18:58:28.000Z"b2694519bbfd590a687bd5f53292421d"82667278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ABT_263_Phase_IIIa_US_and_Australia.pdf2011-01-06T18:58:29.000Z"cabe2174bc4a608439849c15dc77366c"50733278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ABT_263_Phase_IIIa_US_only.pdf2011-01-06T18:58:29.000Z"0146aefc4d7b578545c4be0daa483bc9"50703278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ABT_263_Phase_I_II_US_and_UK.pdf2011-01-06T18:58:29.000Z"c5fc071fd063f4ce17ceba7abcea8a70"50717278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ABT_869_Phase_II_International.pdf2011-01-06T18:58:30.000Z"95268cb5507a3c1c104c371209ce6ad6"74681278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ACRA_Hematological-Malignancies.pdf2011-01-06T18:58:30.000Z"4d5898a8fde7aa494138a3589ccdc25c"1150035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ASCO 2008 Selected Abstracts 04-25-08.xls2011-01-06T18:58:31.000Z"1966575062b9b482eb00cd4f1b5c1fa1"60416278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ASH/ASH_Abstracts_120208.xls2011-01-06T18:58:55.000Z"bb00897181b394cecf8f679471c6e21b"153088278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ASH/ASH_Abstracts_120508.xls2011-01-06T18:58:56.000Z"b600e9d9ad4cb7e98f39fbb7f3b85017"147456278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ASH_$folder$2011-01-06T18:58:31.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Apo2LTRAIL_NHL_PhaseIbandII.pdf2011-01-06T18:58:32.000Z"4983d331f6709f452b303de485e8833f"117454278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Apomab_NHL_PhaseII.pdf2011-01-06T18:58:32.000Z"e0a6351d84e901c0c383d821f8f41144"103033278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Apomab_Phase_ II_ US_and_ Australia.pdf2011-01-06T18:58:33.000Z"45d5d4e1f7743be3f996aee7fbb464bc"46794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/BIONC-21473_M05$w_DR_022504.pdf2011-01-06T18:58:33.000Z"d1775eababa6d0eef88ced7e1302b853"76791278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/BIONC22395_ASCO$ease_050604.pdf2011-01-06T18:58:34.000Z"452fa6ec5d4ede2f728c885420a604c7"67002278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Bevacizumab_ OvCa _PhaseIII.pdf2011-01-06T18:58:34.000Z"c53acb7567c265cec1ef4b1f0d619b39"115807278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Bevacizumab_BC_PhaseIII.pdf2011-01-06T18:58:35.000Z"71994c3c2a1bc1c9e4adf50f97fed9ac"108504278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Bevacizumab_CRC_PhaseIII.pdf2011-01-06T18:58:35.000Z"d3c71c6ec00b0cd18aa19ded8c23e89c"122897278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Bevacizumab_Gastric_PhaseIII.pdf2011-01-06T18:58:36.000Z"05c232f16b2241635af358f40037a427"114650278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Bevacizumab_MM_PhaseII.pdf2011-01-06T18:58:36.000Z"eb7d5af91616072826896375c1f5e2e4"98263278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Bevacizumab_NHL_PhaseIII.pdf2011-01-06T18:58:37.000Z"e3ef987c21d4fbddacc375d2f9a9954f"110462278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Bevacizumab_NSCLCandCRC_PhaseIV.pdf2011-01-06T18:58:37.000Z"b6e683f1254d466986a0aaaccb72d371"128159278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/BioOncClinicalTrials.pdf2011-01-06T18:58:37.000Z"4c404ea64308e83bc45d1cf90961871b"4365542278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Colorectal_Fact_Sheet.pdf2011-01-06T18:58:39.000Z"4334e6271e66ce373dddf1db111c6444"64260278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Erlotinib_2ndLine _NSCLC_PhaseIII.pdf2011-01-06T18:58:39.000Z"787c6e4ac294624049949406f8a5f057"121985278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Erlotinib_Adjuvant _NSCLC_PhaseIII.pdf2011-01-06T18:58:40.000Z"c2b849f0cd9fc2e6d5fd799a155f0ade"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/GDC-0449_MCRC_PhaseII.pdf2011-01-06T18:58:40.000Z"08ecc440f11351c803eaea21924409a5"121380278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/GDC-0449_OvCa_PhaseII.pdf2011-01-06T18:58:41.000Z"d5f45e8e92f095f7b5483291e40b0950"109687278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Genentech_Poster.pdf2011-01-06T18:58:41.000Z"11660522743946832ffe784c6eff94f4"226887278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/GrantApp_7_06.pdf2011-01-06T18:58:42.000Z"f2841dad3522f8e644c86b7600ae8886"526268278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Grant_AppForm2.pdf2011-01-06T18:58:42.000Z"aa9fce650a697877cf25bfbd6eb04b47"38575278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Guide_for_Interpreting_Common_Statistics_Measures_in_Clinical_Trials.pdf2011-01-06T18:58:43.000Z"b57a155f4ea1a94c5ded5538b3d749af"256334278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Hedgehog_antagonist_Phase_II_US_and_Brazil.pdf2011-01-06T18:58:43.000Z"98557d805a3aeebd43edd59f464c89ea"53875278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Hedgehog_antagonist_Phase_II_US_only.pdf2011-01-06T18:58:43.000Z"4e1e5d69a6d80e1a29577c48853a12f6"53808278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/PERTUZUMAB_Phase_III_International.pdf2011-01-06T18:58:44.000Z"aacf0161ee1a5bf19e99a3f05436a34b"82063278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/PRO131921 _Phase _III _US _only_NHL.pdf2011-01-06T18:58:44.000Z"043ecb332b03c6cd0273a04a544862d2"46688278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/PRO131921_CLL_PhaseIandII.pdf2011-01-06T18:58:44.000Z"1b9605b53efff03df8cff061277bf493"93448278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/PRO131921_NHL_PhaseIandII.pdf2011-01-06T18:58:45.000Z"1abb6719912181099018a57f808c1c2b"104609278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/PRO131921_Phase_III_US_only_CLL.pdf2011-01-06T18:58:45.000Z"7c43f92fc0b60ebe4c238878410a6062"45656278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/ResearchGrants.pdf2011-01-06T18:58:46.000Z"3f2e15d3c784cfbab58d046d7d9db491"124285278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN-40_DLBCL_PhaseIIb.pdf2011-01-06T18:58:46.000Z"8d3d17c457b4047c6359fd8e4bbce669"127122278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN-40_DLBCL_PhaseIb.pdf2011-01-06T18:58:46.000Z"2429a44660d2167c7f5749bfacff684d"100672278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN-40_MM_PhaseI.pdf2011-01-06T18:58:47.000Z"8d79ab6e9961cef45ba64c765bb07fcc"106745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN-40_MM_PhaseIb.pdf2011-01-06T18:58:47.000Z"0d11509f68ada61fec0069466bfea871"107612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN-40_NHL_PhaseIb.pdf2011-01-06T18:58:47.000Z"e5239c86c79906f5b30db138b62da94c"107683278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN_40_Phase_IIb_International.pdf2011-01-06T18:58:48.000Z"f4625b13c50156bb7cabb907ca2af44d"54406278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN_40_Phase_I_US_only.pdf2011-01-06T18:58:48.000Z"5821a9684051417e14915a1182c3ec5f"50387278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN_40_Phase_Ib_US_and_the_Netherlands.pdf2011-01-06T18:58:48.000Z"ec5a07a35c552dcbeef88e01d082d053"54556278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN_40_Phase_Ib_US_only_DLBCL.pdf2011-01-06T18:58:48.000Z"0366b30266534906118c90061ebe165d"52055278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/SGN_40_Phase_Ib_US_only_NHL.pdf2011-01-06T18:58:49.000Z"bfc763cbeebd124853ad7c9d413e43bc"52294278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Tarceva_PI.pdf2011-01-06T18:58:49.000Z"a55b08f0fb7a47b5dd3b71caa0f50326"272502278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Trastuzumab_1stLine _MBC_PhaseIII.pdf2011-01-06T18:58:49.000Z"28752f95257c44d239395ec790719a8c"101962278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Trastuzumab_Adjuvant _BC_PhaseIII.pdf2011-01-06T18:58:50.000Z"f81e2ebc6eeba5b831add4e0d2aa66f3"120901278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/Trastuzumab_RecurrentorMetastatic _BC_PhaseIII.pdf2011-01-06T18:58:50.000Z"58805cabd72878b6b103392847230f09"105310278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/avaphysicianSlideKit.pdf2011-01-06T18:58:50.000Z"d8479650c46b6b82ab0b09f6f29c029b"1970612278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/banner/biooncology-banner.swf2011-01-06T18:58:56.000Z"e4ae2aea4a6381a14f0b63d7f3fb4dc5"33568278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/banner/xml/banner.xml2011-01-06T18:58:57.000Z"6f1256045ea982ee6730aa51de5617f8"4464278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/banner/xml_$folder$2011-01-06T18:58:56.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/banner_$folder$2011-01-06T18:58:51.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/biooncology-splash-1.swf2011-01-06T18:58:51.000Z"2caa8afa8559898df0ed5c889fa7083e"289519278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/biooncology-splash-2.swf2011-01-06T18:58:51.000Z"62b3b07135a26612ed50067173e3ecd0"415235278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/chart_3.pdf2011-01-06T18:58:51.000Z"19f06076f462f90ba38ae9b15e57d6d4"2322973278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/facingMCRC.pdf2011-01-06T18:58:52.000Z"76c0af87e5e06d9eb7381e0dabdee205"161128278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/flowplayer/flowplayer.commercial-3.1.5.swf2011-01-06T18:58:57.000Z"6c946296a60f08b375858899882fdd3c"113712278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/flowplayer/flowplayer.controls-3.1.5.swf2011-01-06T18:58:57.000Z"f9aacf3d15ac150b70e828f647b844de"27007278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/flowplayer/flowplayer.controls.swf2011-01-06T18:58:58.000Z"0e88f2ed2b1ec37d3259a1d20ae0f5c7"26583278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/flowplayer/flowplayer.swf2011-01-06T18:58:58.000Z"f09e9408e59396dc3be7619a40b95b45"110762278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/flowplayer_$folder$2011-01-06T18:58:53.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/herceptin-slide-kit.pdf2011-01-06T18:58:53.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resource-library.swf2011-01-06T18:58:54.000Z"95b08f55818159dd23ef1d6875ad21de"24843278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/avastin/avastin-dosing.pdf2011-01-06T18:58:59.000Z"66089f8c744f9d927601afda40c77e3f"636830278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/avastin/avastin-moa-brochure.pdf2011-01-06T18:59:00.000Z"26d031dd895dad1b9aa1bd0f3750e188"1109077278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/avastin/avastin-pi.pdf2011-01-06T18:59:01.000Z"f0a86a766eea99c6db6ad3b56f0db566"306721278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/avastin/avastin-promo-pi.pdf2011-01-06T18:59:01.000Z"e00742790d858dd116cf656d8e3bb3e6"148513278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/avastin_$folder$2011-01-06T18:58:59.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/biooncology/biooncology-poster.pdf2011-01-06T18:59:01.000Z"62774dc3a1449a27be061d14307d8ac7"614488278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/biooncology/biooncology-staging-guidelines.pdf2011-01-06T18:59:02.000Z"f5eae4859ae802f9d12e72e4bbf289b5"973562278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/biooncology/biooncology-targeted-agents.pdf2011-01-06T18:59:02.000Z"1611603248eaab4cc185c75692b93874"1201993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/biooncology_$folder$2011-01-06T18:59:01.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/BCIRG_Sales_Aid_2009.pdf2011-01-06T18:59:03.000Z"2c59410871699cca7993a347dcd4e241"269942278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/HERConnections_SupportLine.pdf2011-01-06T18:59:04.000Z"49e097e35400d09c46dd4f99c83ce8cd"878418278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-adjuvant-english.pdf2011-01-06T18:59:04.000Z"8b2f5a12cdbc5b2412838362f6df8830"1528882278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-adjuvant-spanish.pdf2011-01-06T18:59:05.000Z"e14a72178efb66ccd7017e9acfd502f4"1831910278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-administration.pdf2011-01-06T18:59:05.000Z"6dd7725768b7ce46883a33646ec88aa6"377548278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-bcirg.pdf2011-01-06T18:59:06.000Z"3ccfe628504a07298cc730d0e1f988f5"75345278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-metastatic-english.pdf2011-01-06T18:59:06.000Z"9da7dfb071094ef22a0f57d05ef331fe"479992278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-metastatic-spanish.pdf2011-01-06T18:59:06.000Z"e4d595b501816084d7885e3922d0a4cc"944471278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-metastatic.pdf2011-01-06T18:59:07.000Z"09b0e10ffe011263d6deb3095826bc37"291924278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-pi.pdf2011-01-06T18:59:07.000Z"63d99938bac56e30a600cef260ff3a30"375813278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-promo-pi.pdf2011-01-06T18:59:08.000Z"52984ef23f8f06bb14b15fdb20ffa4e4"233449278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin/herceptin-slide-kit.pdf2011-01-06T18:59:08.000Z"52132ba38789000abe5f2813ec357692"5397123278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/herceptin_$folder$2011-01-06T18:59:03.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/menu-card/menu-card-avastin.pdf2011-01-06T18:59:10.000Z"820191f146c2cf63dde40e4a5986dcc0"724535278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/menu-card/menu-card-herceptin.pdf2011-01-06T18:59:11.000Z"8fd8258618191ee350b13b22d9279c33"753057278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/menu-card/menu-card-tarceva.pdf2011-01-06T18:59:12.000Z"1c051b1c88487cdb5b6b317d176306e5"721884278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/menu-card_$folder$2011-01-06T18:59:09.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/rituxan/rituxan-dosing.pdf2011-01-06T18:59:14.000Z"3fe93a2eb84ffd5cd6c6c20e5b78ad19"2463508278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/rituxan/rituxan-pi.pdf2011-01-06T18:59:14.000Z"60de9fc0f35c5e46cb6d74947bf4266b"209250278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/rituxan/rituxan-promo-pi.pdf2011-01-06T18:59:15.000Z"9659b0ccb1de1254c9da3aea5a61cfd8"294218278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/rituxan_$folder$2011-01-06T18:59:13.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva/Tarceva_SupportLine.pdf2011-01-06T18:59:16.000Z"47d00f9eb54a0a66d7e69cfece45d087"853788278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva/tarceva-champion-kit.pdf2011-01-06T18:59:17.000Z"d7212bc5de6d5832c2c52f2db3680e6d"1641993278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva/tarceva-dosing.pdf2011-01-06T18:59:17.000Z"5acb48bd71a27a98bdc4d05c1f72f5d8"342787278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva/tarceva-nsclc-moa.pdf2011-01-06T18:59:18.000Z"e6352941a6163d46716aec3d7b768573"676096278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva/tarceva-nsclc.pdf2011-01-06T18:59:18.000Z"acf888034d84e1b8536a4ebe04055dad"421468278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva/tarceva-pc.pdf2011-01-06T18:59:19.000Z"f7753d8f13adecf268e0ee2388f0bb98"294040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva/tarceva-pi.pdf2011-01-06T18:59:19.000Z"d55b25610d0d6c57748eb5622b8443f1"2895045278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva/tarceva-promo-pi.pdf2011-01-06T18:59:20.000Z"a045dcdf5e975c4eda78dbf08019c0a3"3400035278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva/tarceva-rash.pdf2011-01-06T18:59:21.000Z"c11aee7f57dd2ea52214ce92e1481514"1479745278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/tarceva_$folder$2011-01-06T18:59:16.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/xeloda/xeloda-brochure.pdf2011-01-06T18:59:22.000Z"bf5e4dd5cc9f34a7dd0e15929a7cfb70"3766040278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/xeloda/xeloda-dosing.pdf2011-01-06T18:59:23.000Z"ce3787c0b335eef167ee561d69f72cbb"212908278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/xeloda/xeloda-is.pdf2011-01-06T18:59:24.000Z"77f67637b3512116d005acb887631a1b"586976278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/xeloda/xeloda-moa.pdf2011-01-06T18:59:24.000Z"9601ba6c29ff03591464a445085940cf"71030278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/xeloda/xeloda-promo-pi.pdf2011-01-06T18:59:25.000Z"3966b2d3f6be8276925b466d329a8c70"5862223278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/xeloda/xeloda-support.pdf2011-01-06T18:59:25.000Z"94a8684dd01699bdc99308003037bb73"4452414278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/xeloda/xeloda-tp.pdf2011-01-06T18:59:26.000Z"76e6045c1e5358cbdb75eec5ffb3fa95"1149226278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources/xeloda_$folder$2011-01-06T18:59:21.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/resources_$folder$2011-01-06T18:58:54.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/startingTherapyWithAvastin.pdf2011-01-06T18:58:54.000Z"feb1e5f35e7b24a057c9fbe35d0a871e"600844278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/timeline/timeline.swf2011-01-06T18:59:26.000Z"d5d70aeef08bff987f8c5e8e78247b2d"114441278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/timeline/xml/timeline.xml2011-01-06T18:59:27.000Z"f1cb30b52f3f6b15b178b2284f1a0f2c"11794278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/timeline/xml_$folder$2011-01-06T18:59:27.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/timeline_$folder$2011-01-06T18:58:55.000Z"d41d8cd98f00b204e9800998ecf8427e"0278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/video/Anti-NRP1/10026901_Angiogenesis_NME_NRP1.flv2011-01-06T18:59:28.000Z"9b948b14d41e6302924847ebc0cf4542"2039308278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/video/Anti-NRP1/10026901_angiogenesis_nme_nrp1.mp42011-10-10T21:31:20.000Z"e3c358a2fc497d7ead30167ea8418f63"2163601278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/video/Anti-NRP1/10026901_angiogenesis_nme_nrp1.ogg2011-10-10T21:31:22.000Z"bf44612c6652c7fd4375c15abceea262"1755661278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/video/Anti-NRP1/10026901_angiogenesis_nme_nrp1.webm2011-10-10T21:31:24.000Z"41f3cbe0eb0cc0ca992dacd9b4c74d64"1511291278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/video/Anti-NRP1/config.xml2011-01-06T18:59:28.000Z"d0384df583a71475522c4e9899cad906"287278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/video/Anti-NRP1/thumbnails/10026901_angiogenesis_nme_nrp1_0000.jpg2011-10-10T21:31:57.000Z"adbc00e41d534d932a2e34e2bf46a1e6"14045278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/video/Anti-NRP1/thumbnails/10026901_angiogenesis_nme_nrp1_0001.jpg2011-10-10T21:31:57.000Z"5c1d0ee7b1f64b8b13c8b749730ad9a0"14060278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/video/Anti-NRP1/thumbnails/10026901_angiogenesis_nme_nrp1_0002.jpg2011-10-10T21:31:58.000Z"0f5678ab3eada3ddac409df8b06f33ad"16574278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARDmedia/20110106/video/Anti-NRP1/thumbnails/10026901_angiogenesis_nme_nrp1_0003.jpg2011-10-10T21:31:58.000Z"bd63ba41735bd1db4b3bef15513230e6"15221278cff8ff5686751264b24a92439bc85d4e88282693d91702a4e9d288a102a99cirrusSTANDARD